data_2mw3_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mw3 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.975 0.417 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.413 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.3 mp 37.24 81.58 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.533 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.55 168.34 35.38 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.8 m -93.07 -17.62 23.61 Favored 'General case' 0 N--CA 1.466 0.325 0 O-C-N 122.664 -0.315 . . . . 0.0 110.929 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.57 145.03 78.13 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.773 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.41 -19.54 37.66 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.535 2.157 . . . . 0.0 112.178 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -88.86 166.08 14.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.843 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -101.53 159.67 15.1 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.282 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.4 OUTLIER -91.1 -93.9 0.13 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.564 179.597 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.51 -24.85 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.444 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.505 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.08 -0.99 57.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.359 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.73 -9.85 72.35 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -82.71 152.8 67.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -41.88 118.25 0.88 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 122.458 2.106 . . . . 0.0 111.99 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.09 159.53 31.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.969 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.465 0.301 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.206 -179.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.003 0.43 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.453 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.1 mp 38.07 79.14 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.72 178.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.28 -177.27 33.22 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.1 m -111.19 -23.89 10.6 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 t -52.18 145.31 19.02 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.709 -179.257 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -68.4 -15.12 41.6 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.338 2.025 . . . . 0.0 111.905 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.465 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.5 m-85 -88.09 156.08 19.46 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.01 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -99.27 153.86 18.62 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.226 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.415 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.6 OUTLIER -88.48 -93.44 0.11 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.631 -179.737 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -131.24 -24.88 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.914 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.533 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 2.9 mm? -89.74 -5.57 56.86 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.541 -0.463 . . . . 0.0 110.533 -179.474 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.06 -26.94 18.6 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -61.33 168.93 2.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -62.35 144.04 94.58 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 121.44 1.426 . . . . 0.0 112.025 -178.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -89.85 153.76 20.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.706 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.463 0.215 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.402 -179.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.941 0.4 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 13.4 mt 38.85 77.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.649 178.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.89 169.47 35.19 Favored Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.392 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 64.3 m -98.06 -6.01 32.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.619 0.247 . . . . 0.0 111.152 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -71.59 144.59 88.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.8 -179.355 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.96 -15.84 40.43 Favored 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.195 1.93 . . . . 0.0 112.13 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.8 m-85 -88.21 160.7 17.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.382 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -100.21 153.17 19.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.432 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.03 -96.85 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.827 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.6 pt -129.62 -21.38 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.568 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.0 mt -91.13 -2.81 57.5 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.541 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.53 53.87 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -77.83 151.11 79.26 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.228 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -36.02 139.85 0.15 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.835 2.357 . . . . 0.0 111.881 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -94.72 160.01 14.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.34 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.466 0.362 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.594 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 99.3 p . . . . . 0 CA--C 1.523 -0.081 0 CA-C-O 120.847 0.356 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.41 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.4 mp 38.19 79.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.033 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -165.67 178.69 40.37 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.2 p -107.43 -31.75 8.02 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.789 0.328 . . . . 0.0 111.345 -179.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 t -39.84 130.55 1.51 Allowed Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.21 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -49.21 -26.94 11.91 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.818 1.678 . . . . 0.0 112.28 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.23 161.87 16.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.076 -178.778 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' A' ' 8' ' ' ASN . 4.8 p-10 -100.68 170.9 8.04 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.455 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -91.22 -97.95 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.105 179.705 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.7 mt -131.53 -22.45 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.478 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.7 mt -87.24 -4.21 59.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.901 0.382 . . . . 0.0 110.409 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -15.56 63.07 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 16.8 m-85 -75.77 158.21 83.04 Favored Pre-proline 0 C--N 1.328 -0.368 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.99 132.49 47.72 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.558 1.506 . . . . 0.0 111.74 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -87.52 160.18 18.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.692 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.642 -179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.4 p . . . . . 0 N--CA 1.455 -0.207 0 CA-C-O 120.714 0.292 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.5 mt 41.12 60.97 1.88 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.143 0.497 . . . . 0.0 111.026 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.51 -169.48 14.87 Favored Glycine 0 CA--C 1.521 0.459 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.2 m -136.77 0.63 2.46 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.789 0.328 . . . . 0.0 110.485 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 5.5 t -66.43 142.84 97.94 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.714 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -45.91 -38.53 18.37 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.887 1.725 . . . . 0.0 112.294 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.489 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 4.3 m-85 -88.61 163.96 15.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.318 -179.273 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -101.56 171.19 7.71 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.186 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -89.65 -94.54 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.393 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.7 -23.71 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 29.1 mt -86.36 -2.03 58.06 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.3 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.37 -12.78 68.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -82.08 150.66 65.33 Favored Pre-proline 0 C--N 1.33 -0.279 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -40.61 133.94 2.32 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 122.597 2.198 . . . . 0.0 112.049 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.426 ' O ' ' CB ' ' A' ' 5' ' ' SER . . . -88.15 161.16 17.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.027 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.383 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.864 0.364 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 mt 41.86 66.32 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.746 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.48 -171.35 17.25 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.6 m -130.2 -3.94 4.42 Favored 'General case' 0 C--N 1.331 -0.207 0 O-C-N 122.752 -0.263 . . . . 0.0 110.512 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.1 t -66.46 140.19 96.49 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.734 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -45.74 -37.24 15.84 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.64 2.227 . . . . 0.0 112.25 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.492 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.1 m-85 -89.42 164.35 14.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.495 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 71.7 m-80 -101.36 173.13 6.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.982 0.42 . . . . 0.0 110.449 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.42 -81.9 0.25 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.334 179.749 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.6 pt -148.46 -36.6 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.49 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 75.5 mt -66.76 -40.95 88.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.654 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.48 -27.6 2.36 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -72.44 156.83 89.96 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.621 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -49.38 138.49 30.27 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.332 2.021 . . . . 0.0 112.192 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -85.27 164.0 18.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.282 179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.827 0.346 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.5 mt 39.67 79.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.216 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.19 39.25 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.9 m -106.0 -25.86 11.91 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.893 0.378 . . . . 0.0 110.562 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.416 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.3 OUTLIER -48.08 145.4 5.07 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.661 -179.355 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -68.79 -18.99 41.58 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.528 2.152 . . . . 0.0 112.18 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.468 ' O ' ' N ' ' A' ' 15' ' ' ALA . 91.2 m-85 -88.61 156.93 18.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.479 ' OD1' ' N ' ' A' ' 8' ' ' ASN . 3.1 p-10 -96.27 155.77 16.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.915 0.388 . . . . 0.0 110.283 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.55 -92.01 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.392 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.8 mt -132.56 -25.68 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.529 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 66.8 mt -88.84 -1.55 58.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.538 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.69 -11.4 68.69 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -82.04 150.69 65.54 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.833 0.349 . . . . 0.0 110.356 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -36.76 132.53 0.4 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.736 2.291 . . . . 0.0 111.893 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.468 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -87.4 157.14 19.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.972 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.324 -0.509 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.276 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 75.6 p . . . . . 0 N--CA 1.457 -0.12 0 CA-C-O 120.994 0.426 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.4 mt 41.58 67.98 0.5 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.521 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.3 -166.28 14.82 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.2 m -134.72 -0.33 2.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.768 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.48 ' N ' ' O ' ' A' ' 15' ' ' ALA . 5.7 t -64.21 141.79 98.17 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.686 -179.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -46.56 -39.4 22.77 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 121.914 1.743 . . . . 0.0 112.739 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.479 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 6.7 m-85 -89.05 167.95 12.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.384 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -100.76 171.04 7.93 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.183 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.535 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.0 OUTLIER -88.13 -92.4 0.11 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.061 -179.698 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 97.0 mt -134.67 -39.47 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.874 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.9 mt -67.49 -39.91 85.23 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.44 -24.2 3.08 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -68.76 158.96 84.32 Favored Pre-proline 0 C--N 1.33 -0.244 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.31 130.72 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.017 1.811 . . . . 0.0 112.125 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.48 ' O ' ' N ' ' A' ' 5' ' ' SER . . . -74.95 152.25 38.8 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.382 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.788 0.328 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.413 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.4 mp 37.47 78.73 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.282 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.11 170.82 34.97 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 t -88.59 -40.74 13.14 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.082 0.468 . . . . 0.0 110.771 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.6 OUTLIER -40.51 143.65 0.65 Allowed Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.183 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -71.85 -12.99 29.14 Favored 'Trans proline' 0 N--CA 1.498 1.74 0 C-N-CA 122.353 2.035 . . . . 0.0 111.846 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.8 m-85 -88.38 161.82 16.87 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.413 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.419 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 98.9 m-20 -98.26 156.16 16.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.237 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.524 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.82 -99.03 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.411 179.75 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.3 pt -128.63 -19.77 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.598 -0.274 . . . . 0.0 110.504 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.3 mt -91.87 -5.42 53.35 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 120.544 -0.463 . . . . 0.0 110.303 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.419 ' O ' ' ND2' ' A' ' 8' ' ' ASN . . . 94.86 -8.88 70.78 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.427 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 8.9 m-85 -86.05 153.7 57.31 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.825 0.345 . . . . 0.0 110.154 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -37.23 141.49 0.18 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 123.0 2.466 . . . . 0.0 112.0 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -99.45 155.32 17.62 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.703 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.464 0.264 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.483 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 84.0 p . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.909 0.385 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.416 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.3 mp 38.04 72.14 0.13 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.135 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.61 -167.42 19.37 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.6 m -135.58 1.3 2.83 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.704 0.288 . . . . 0.0 110.847 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 7.0 t -66.96 144.6 98.62 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.028 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -51.06 -34.94 49.15 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 121.806 1.671 . . . . 0.0 112.075 178.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.46 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 15.7 m-85 -88.04 160.29 17.91 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.065 -178.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -100.25 164.64 11.86 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.285 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.69 -96.88 0.09 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.459 -179.385 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.59 -24.41 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.78 0.324 . . . . 0.0 110.486 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.53 -5.43 58.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.906 0.384 . . . . 0.0 110.285 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.44 -9.19 74.49 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.48 160.92 71.58 Favored Pre-proline 0 C--N 1.33 -0.245 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.99 134.57 56.13 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.755 1.637 . . . . 0.0 111.795 -179.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.421 ' O ' ' CB ' ' A' ' 5' ' ' SER . . . -86.15 156.33 20.39 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.454 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.537 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 38.1 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.889 0.376 . . . . 0.0 110.638 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.9 mt 39.6 78.03 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.519 178.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -162.9 176.52 39.17 Favored Glycine 0 CA--C 1.529 0.934 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.216 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.3 m -107.93 -9.98 15.6 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.545 0.212 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.431 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -65.34 146.23 98.98 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.57 -179.502 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.2 -16.0 39.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 122.477 2.118 . . . . 0.0 112.264 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.479 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.7 m-85 -88.23 154.44 20.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.181 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -96.49 152.6 18.47 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.172 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.16 -92.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.207 -179.725 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.73 -24.85 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.632 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 mt -90.13 -2.68 58.11 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.763 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.8 -21.13 37.95 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.2 m-85 -70.78 154.29 94.38 Favored Pre-proline 0 C--N 1.329 -0.322 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -44.55 136.88 8.77 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.072 1.848 . . . . 0.0 112.065 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.479 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -88.52 156.62 18.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.53 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.31 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 120.781 0.324 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.2 mp 35.75 79.74 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.534 179.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.69 176.38 35.59 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.6 m -105.43 -3.3 22.74 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.625 0.25 . . . . 0.0 111.091 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 1.1 t -74.94 145.36 81.07 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.554 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.34 -15.1 38.45 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.293 1.996 . . . . 0.0 111.801 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.456 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.6 m-85 -88.41 161.07 17.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.35 -179.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -100.06 153.21 19.4 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.836 0.35 . . . . 0.0 110.604 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.2 OUTLIER -88.0 -84.46 0.2 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.84 -179.781 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 15.6 pt -143.69 -23.03 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.645 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 84.6 mt -88.12 -5.83 58.23 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.075 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.61 -19.06 55.67 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -71.41 172.01 7.69 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -62.13 143.27 94.43 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 121.654 1.569 . . . . 0.0 111.8 -178.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.456 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -92.25 155.72 17.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.173 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.466 0.368 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.544 -179.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . 0.42 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.8 mp 37.93 79.2 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.617 179.171 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.85 165.31 34.6 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.3 m -91.12 -12.06 36.68 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.628 0.251 . . . . 0.0 111.35 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.447 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -65.36 144.49 99.0 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.7 -179.37 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.76 -15.76 37.25 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.354 2.036 . . . . 0.0 111.785 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.506 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.6 m-85 -88.65 161.43 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.291 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -99.26 156.82 16.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.397 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.06 -91.97 0.11 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.123 -179.639 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.6 mt -132.89 -26.23 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.567 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . 0.516 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.05 -3.84 58.56 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.795 -179.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.4 -10.12 71.41 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 18.0 m-85 -83.16 152.54 65.2 Favored Pre-proline 0 C--N 1.329 -0.292 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -37.45 140.08 0.24 Allowed 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.774 2.316 . . . . 0.0 111.997 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -96.77 155.17 16.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.569 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.464 0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.608 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.1 p . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.113 0.482 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 36.9 77.34 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.865 178.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.18 36.33 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.185 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.4 m -97.51 -5.0 36.84 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.815 -0.226 . . . . 0.0 111.431 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -73.5 146.55 86.33 Favored Pre-proline 0 CA--C 1.539 0.546 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.747 -179.394 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -70.92 -14.56 32.51 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.479 2.12 . . . . 0.0 112.238 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.492 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.9 m-85 -88.47 155.55 19.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.794 0.33 . . . . 0.0 110.608 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -95.46 154.05 17.4 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.695 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.97 -95.87 0.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.16 -179.483 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.06 -24.14 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.558 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.7 mt -90.67 -4.72 56.56 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.808 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.89 -17.35 58.88 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -70.47 170.83 9.33 Favored Pre-proline 0 C--N 1.33 -0.265 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -62.11 142.71 93.15 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 121.878 1.719 . . . . 0.0 111.835 -178.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.492 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -93.41 153.47 18.48 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.663 -0.698 . . . . 0.0 111.198 -178.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.681 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.0 p . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.75 0.309 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 41.38 77.55 0.06 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.214 0.531 . . . . 0.0 111.44 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -166.04 175.51 41.57 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.4 m -113.17 -1.94 14.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.449 0.166 . . . . 0.0 110.726 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.5 t -66.52 134.06 94.38 Favored Pre-proline 0 CA--C 1.538 0.487 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.736 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -47.65 -31.08 13.59 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 121.794 1.663 . . . . 0.0 112.516 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . 0.564 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.1 161.94 17.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.197 -178.845 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -100.59 170.28 8.48 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.19 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.0 OUTLIER -89.83 -87.23 0.18 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.192 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.0 pt -146.36 -18.64 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.655 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.1 mt -89.0 -1.73 58.25 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.862 0.363 . . . . 0.0 110.03 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.42 -13.76 66.84 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 36.1 m-85 -81.48 154.43 71.43 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -49.55 128.8 21.72 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 121.969 1.779 . . . . 0.0 112.112 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -83.48 162.49 20.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.618 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.585 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.975 0.417 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.413 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.3 mp 37.24 81.58 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.533 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.55 168.34 35.38 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.8 m -93.07 -17.62 23.61 Favored 'General case' 0 N--CA 1.466 0.325 0 O-C-N 122.664 -0.315 . . . . 0.0 110.929 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.434 ' OG ' ' O ' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -58.57 145.03 78.13 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.773 -179.134 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.41 -19.54 37.66 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.535 2.157 . . . . 0.0 112.178 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -88.86 166.08 14.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.843 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.8 p30 -101.53 159.67 15.1 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.282 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.4 OUTLIER -91.1 -93.9 0.13 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.564 179.597 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.51 -24.85 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.444 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.505 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.08 -0.99 57.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.359 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.73 -9.85 72.35 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -82.71 152.8 67.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -41.88 118.25 0.88 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 122.458 2.106 . . . . 0.0 111.99 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.09 159.53 31.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.969 179.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.17 46.37 0.92 Allowed 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.206 -179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.434 ' O ' ' OG ' ' A' ' 5' ' ' SER . 89.3 mt -89.69 111.1 22.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 179.492 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -139.63 168.09 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.284 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.41 HG22 HD11 ' A' ' 19' ' ' ILE . 96.3 mt -87.32 -13.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.556 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -143.01 149.55 49.63 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.514 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.491 1.372 0 C-N-CA 122.366 2.044 . . . . 0.0 111.963 179.76 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.003 0.43 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.453 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.1 mp 38.07 79.14 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.72 178.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.28 -177.27 33.22 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.1 m -111.19 -23.89 10.6 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.424 ' HB2' ' H ' ' A' ' 17' ' ' ILE . 1.3 t -52.18 145.31 19.02 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.709 -179.257 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -68.4 -15.12 41.6 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.338 2.025 . . . . 0.0 111.905 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.465 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.5 m-85 -88.09 156.08 19.46 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.01 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -99.27 153.86 18.62 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.226 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.415 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.6 OUTLIER -88.48 -93.44 0.11 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.631 -179.737 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -131.24 -24.88 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.914 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.533 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 2.9 mm? -89.74 -5.57 56.86 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.541 -0.463 . . . . 0.0 110.533 -179.474 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.06 -26.94 18.6 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -61.33 168.93 2.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -62.35 144.04 94.58 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 121.44 1.426 . . . . 0.0 112.025 -178.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -89.85 153.76 20.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.706 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.55 59.0 0.74 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.402 -179.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.424 ' H ' ' HB2' ' A' ' 5' ' ' SER . 97.4 mt -89.02 -40.13 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.469 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -88.71 27.45 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 110.429 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 21.1 tt -89.16 -15.04 9.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.63 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 50.79 76.54 0.53 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.405 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_exo . . . . . 0 C--N 1.308 -1.559 0 C-N-CA 122.629 2.219 . . . . 0.0 112.17 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.941 0.4 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 13.4 mt 38.85 77.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.649 178.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.89 169.47 35.19 Favored Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.392 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 64.3 m -98.06 -6.01 32.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.619 0.247 . . . . 0.0 111.152 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -71.59 144.59 88.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.8 -179.355 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.96 -15.84 40.43 Favored 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.195 1.93 . . . . 0.0 112.13 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.8 m-85 -88.21 160.7 17.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.382 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -100.21 153.17 19.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.432 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.03 -96.85 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.827 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.6 pt -129.62 -21.38 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.568 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.0 mt -91.13 -2.81 57.5 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.541 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.53 53.87 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -77.83 151.11 79.26 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.228 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -36.02 139.85 0.15 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.835 2.357 . . . . 0.0 111.881 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -94.72 160.01 14.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.34 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.57 51.17 0.8 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.594 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 40.8 pt -89.33 12.3 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.547 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.406 ' CG1' ' H ' ' A' ' 19' ' ' ILE . 1.4 t -77.48 -148.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.105 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.416 HD13 HG23 ' A' ' 19' ' ' ILE . 96.4 mt -89.83 -39.53 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.683 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -43.25 147.96 0.68 Allowed Pre-proline 0 CA--C 1.534 0.357 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.661 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo . . . . . 0 N--CA 1.49 1.296 0 C-N-CA 122.29 1.993 . . . . 0.0 111.995 179.639 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 99.3 p . . . . . 0 CA--C 1.523 -0.081 0 CA-C-O 120.847 0.356 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.41 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.4 mp 38.19 79.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.033 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -165.67 178.69 40.37 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.2 p -107.43 -31.75 8.02 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.789 0.328 . . . . 0.0 111.345 -179.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.426 ' OG ' ' O ' ' A' ' 17' ' ' ILE . 2.3 t -39.84 130.55 1.51 Allowed Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.21 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -49.21 -26.94 11.91 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.818 1.678 . . . . 0.0 112.28 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.23 161.87 16.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.076 -178.778 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' A' ' 8' ' ' ASN . 4.8 p-10 -100.68 170.9 8.04 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.455 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -91.22 -97.95 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.105 179.705 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.7 mt -131.53 -22.45 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.478 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.7 mt -87.24 -4.21 59.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.901 0.382 . . . . 0.0 110.409 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -15.56 63.07 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 16.8 m-85 -75.77 158.21 83.04 Favored Pre-proline 0 C--N 1.328 -0.368 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.99 132.49 47.72 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.558 1.506 . . . . 0.0 111.74 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -87.52 160.18 18.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.692 -179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.02 41.71 1.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.642 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.426 ' O ' ' OG ' ' A' ' 5' ' ' SER . 96.8 mt -89.85 124.92 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.463 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -124.7 -94.44 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.415 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.411 HD11 HG21 ' A' ' 19' ' ' ILE . 96.9 mt -136.16 -36.41 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.585 ' N ' ' CD ' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -78.5 -43.55 2.01 Favored Pre-proline 0 CA--C 1.533 0.326 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.298 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 20' ' ' TYR . 52.1 Cg_exo . . . . . 0 N--CA 1.496 1.622 0 C-N-CA 122.495 2.13 . . . . 0.0 112.16 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.4 p . . . . . 0 N--CA 1.455 -0.207 0 CA-C-O 120.714 0.292 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.5 mt 41.12 60.97 1.88 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.143 0.497 . . . . 0.0 111.026 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.51 -169.48 14.87 Favored Glycine 0 CA--C 1.521 0.459 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.2 m -136.77 0.63 2.46 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.789 0.328 . . . . 0.0 110.485 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 5.5 t -66.43 142.84 97.94 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.714 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -45.91 -38.53 18.37 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.887 1.725 . . . . 0.0 112.294 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.489 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 4.3 m-85 -88.61 163.96 15.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.318 -179.273 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -101.56 171.19 7.71 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.186 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -89.65 -94.54 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.393 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.7 -23.71 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 29.1 mt -86.36 -2.03 58.06 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.3 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.37 -12.78 68.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -82.08 150.66 65.33 Favored Pre-proline 0 C--N 1.33 -0.279 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -40.61 133.94 2.32 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 122.597 2.198 . . . . 0.0 112.049 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.426 ' O ' ' CB ' ' A' ' 5' ' ' SER . . . -88.15 161.16 17.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.027 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.24 62.12 0.69 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.383 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 17' ' ' ILE . 23.5 pt -89.28 17.88 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.524 179.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.2 m -74.98 159.34 5.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.388 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.9 tt -88.06 -38.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.591 -179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -86.48 151.35 53.18 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.485 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo . . . . . 0 C--N 1.313 -1.319 0 C-N-CA 122.495 2.13 . . . . 0.0 111.994 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.864 0.364 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.9 mt 41.86 66.32 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.746 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.48 -171.35 17.25 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.6 m -130.2 -3.94 4.42 Favored 'General case' 0 C--N 1.331 -0.207 0 O-C-N 122.752 -0.263 . . . . 0.0 110.512 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.406 ' OG ' ' CG1' ' A' ' 17' ' ' ILE . 6.1 t -66.46 140.19 96.49 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.734 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -45.74 -37.24 15.84 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.64 2.227 . . . . 0.0 112.25 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.492 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.1 m-85 -89.42 164.35 14.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.495 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 71.7 m-80 -101.36 173.13 6.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.982 0.42 . . . . 0.0 110.449 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.42 -81.9 0.25 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.334 179.749 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.6 pt -148.46 -36.6 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.49 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 75.5 mt -66.76 -40.95 88.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.654 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.48 -27.6 2.36 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -72.44 156.83 89.96 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.621 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -49.38 138.49 30.27 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.332 2.021 . . . . 0.0 112.192 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -85.27 164.0 18.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -118.64 67.16 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.282 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.406 ' CG1' ' OG ' ' A' ' 5' ' ' SER . 5.7 pt -88.9 115.47 28.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.299 0.571 . . . . 0.0 110.385 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -142.66 141.73 27.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.412 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.0 mt -89.72 -17.67 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.769 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.585 ' O ' ' CD2' ' A' ' 20' ' ' TYR . 13.5 p90 -124.92 80.0 63.96 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.085 0.469 . . . . 0.0 110.476 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo . . . . . 0 C--N 1.307 -1.643 0 C-N-CA 122.741 2.294 . . . . 0.0 112.073 -179.918 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.827 0.346 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.5 mt 39.67 79.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.216 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.19 39.25 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.9 m -106.0 -25.86 11.91 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.893 0.378 . . . . 0.0 110.562 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.455 ' OG ' ' O ' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -48.08 145.4 5.07 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.661 -179.355 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -68.79 -18.99 41.58 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.528 2.152 . . . . 0.0 112.18 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.468 ' O ' ' N ' ' A' ' 15' ' ' ALA . 91.2 m-85 -88.61 156.93 18.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.479 ' OD1' ' N ' ' A' ' 8' ' ' ASN . 3.1 p-10 -96.27 155.77 16.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.915 0.388 . . . . 0.0 110.283 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.55 -92.01 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.392 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.8 mt -132.56 -25.68 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.529 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 66.8 mt -88.84 -1.55 58.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.538 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.69 -11.4 68.69 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -82.04 150.69 65.54 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.833 0.349 . . . . 0.0 110.356 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -36.76 132.53 0.4 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.736 2.291 . . . . 0.0 111.893 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.468 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -87.4 157.14 19.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.972 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -100.74 39.41 1.38 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.276 -179.601 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.455 ' O ' ' OG ' ' A' ' 5' ' ' SER . 96.6 mt -89.24 124.44 41.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.252 179.837 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.7 t -140.12 -90.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.774 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 19.8 tt -96.95 -13.89 7.95 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-O 120.762 0.315 . . . . 0.0 110.336 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.447 ' CD1' ' C ' ' A' ' 20' ' ' TYR . 19.4 p90 -141.69 146.31 40.83 Favored Pre-proline 0 CA--C 1.536 0.424 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo . . . . . 0 N--CA 1.496 1.621 0 C-N-CA 122.448 2.099 . . . . 0.0 111.855 179.191 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 75.6 p . . . . . 0 N--CA 1.457 -0.12 0 CA-C-O 120.994 0.426 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.4 mt 41.58 67.98 0.5 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.521 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.3 -166.28 14.82 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.2 m -134.72 -0.33 2.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.768 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.48 ' N ' ' O ' ' A' ' 15' ' ' ALA . 5.7 t -64.21 141.79 98.17 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.686 -179.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -46.56 -39.4 22.77 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 121.914 1.743 . . . . 0.0 112.739 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.479 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 6.7 m-85 -89.05 167.95 12.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.384 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -100.76 171.04 7.93 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.183 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.535 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.0 OUTLIER -88.13 -92.4 0.11 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.061 -179.698 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 97.0 mt -134.67 -39.47 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.874 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.9 mt -67.49 -39.91 85.23 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.44 -24.2 3.08 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -68.76 158.96 84.32 Favored Pre-proline 0 C--N 1.33 -0.244 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.31 130.72 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.017 1.811 . . . . 0.0 112.125 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.48 ' O ' ' N ' ' A' ' 5' ' ' SER . . . -74.95 152.25 38.8 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -96.57 35.86 1.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.382 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.433 ' O ' ' OG ' ' A' ' 5' ' ' SER . 96.6 mt -92.68 113.49 27.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.269 179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.0 t -146.83 -80.99 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.12 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -93.03 -50.11 12.45 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.572 -0.285 . . . . 0.0 110.825 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.405 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.7 p90 -102.25 151.23 38.08 Favored Pre-proline 0 N--CA 1.467 0.414 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo . . . . . 0 N--CA 1.493 1.472 0 C-N-CA 122.541 2.16 . . . . 0.0 111.762 179.54 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.788 0.328 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.413 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.4 mp 37.47 78.73 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.282 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.11 170.82 34.97 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 t -88.59 -40.74 13.14 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.082 0.468 . . . . 0.0 110.771 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.6 OUTLIER -40.51 143.65 0.65 Allowed Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.183 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -71.85 -12.99 29.14 Favored 'Trans proline' 0 N--CA 1.498 1.74 0 C-N-CA 122.353 2.035 . . . . 0.0 111.846 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.8 m-85 -88.38 161.82 16.87 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.413 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.419 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 98.9 m-20 -98.26 156.16 16.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.237 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.524 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.82 -99.03 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.411 179.75 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.3 pt -128.63 -19.77 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.598 -0.274 . . . . 0.0 110.504 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.3 mt -91.87 -5.42 53.35 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 120.544 -0.463 . . . . 0.0 110.303 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.419 ' O ' ' ND2' ' A' ' 8' ' ' ASN . . . 94.86 -8.88 70.78 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.427 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 8.9 m-85 -86.05 153.7 57.31 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.825 0.345 . . . . 0.0 110.154 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -37.23 141.49 0.18 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 123.0 2.466 . . . . 0.0 112.0 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -99.45 155.32 17.62 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.703 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -110.5 51.93 0.75 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.483 -179.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.0 pt -90.32 5.51 5.27 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.883 0.373 . . . . 0.0 110.545 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.8 m -72.99 171.83 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 16.4 tt -87.76 -27.57 5.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.735 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -73.32 146.84 87.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.425 -179.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo . . . . . 0 N--CA 1.492 1.404 0 C-N-CA 122.152 1.901 . . . . 0.0 112.315 179.677 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 84.0 p . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.909 0.385 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.416 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.3 mp 38.04 72.14 0.13 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.135 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.61 -167.42 19.37 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.6 m -135.58 1.3 2.83 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.704 0.288 . . . . 0.0 110.847 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 7.0 t -66.96 144.6 98.62 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.028 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -51.06 -34.94 49.15 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 121.806 1.671 . . . . 0.0 112.075 178.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.46 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 15.7 m-85 -88.04 160.29 17.91 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.065 -178.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -100.25 164.64 11.86 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.285 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.69 -96.88 0.09 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.459 -179.385 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.59 -24.41 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.78 0.324 . . . . 0.0 110.486 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.53 -5.43 58.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.906 0.384 . . . . 0.0 110.285 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.44 -9.19 74.49 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.48 160.92 71.58 Favored Pre-proline 0 C--N 1.33 -0.245 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.99 134.57 56.13 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.755 1.637 . . . . 0.0 111.795 -179.262 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.421 ' O ' ' CB ' ' A' ' 5' ' ' SER . . . -86.15 156.33 20.39 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.454 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -109.63 50.2 0.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.537 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.8 pt -89.36 45.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.849 0.357 . . . . 0.0 110.705 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.6 m -88.9 172.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.418 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 20.4 tt -88.61 -38.13 11.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.689 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 3.2 p90 -82.31 152.56 67.79 Favored Pre-proline 0 CA--C 1.535 0.376 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.103 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo . . . . . 0 N--CA 1.49 1.294 0 C-N-CA 122.404 2.069 . . . . 0.0 112.393 179.681 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 38.1 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.889 0.376 . . . . 0.0 110.638 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.9 mt 39.6 78.03 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.519 178.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -162.9 176.52 39.17 Favored Glycine 0 CA--C 1.529 0.934 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.216 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.3 m -107.93 -9.98 15.6 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.545 0.212 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.431 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -65.34 146.23 98.98 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.57 -179.502 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.2 -16.0 39.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 122.477 2.118 . . . . 0.0 112.264 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.479 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.7 m-85 -88.23 154.44 20.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.181 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -96.49 152.6 18.47 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.172 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.16 -92.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.207 -179.725 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.73 -24.85 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.632 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 mt -90.13 -2.68 58.11 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.763 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.8 -21.13 37.95 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.2 m-85 -70.78 154.29 94.38 Favored Pre-proline 0 C--N 1.329 -0.322 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -44.55 136.88 8.77 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.072 1.848 . . . . 0.0 112.065 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.479 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -88.52 156.62 18.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.53 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -100.58 43.59 1.05 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.31 -179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.403 HD12 HG22 ' A' ' 17' ' ' ILE . 96.5 mt -89.82 117.41 33.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.226 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.8 m -137.03 167.47 23.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.226 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.9 mm -86.62 -38.86 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.865 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.571 ' O ' ' CD2' ' A' ' 20' ' ' TYR . 14.8 p90 -116.15 82.65 11.63 Favored Pre-proline 0 N--CA 1.468 0.428 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.584 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_exo . . . . . 0 C--N 1.307 -1.621 0 C-N-CA 122.296 1.998 . . . . 0.0 112.147 179.938 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 120.781 0.324 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 10.2 mp 35.75 79.74 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.534 179.327 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.69 176.38 35.59 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.6 m -105.43 -3.3 22.74 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.625 0.25 . . . . 0.0 111.091 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 1.1 t -74.94 145.36 81.07 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.554 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.34 -15.1 38.45 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.293 1.996 . . . . 0.0 111.801 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.456 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.6 m-85 -88.41 161.07 17.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.35 -179.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -100.06 153.21 19.4 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.836 0.35 . . . . 0.0 110.604 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.2 OUTLIER -88.0 -84.46 0.2 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.84 -179.781 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 15.6 pt -143.69 -23.03 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.645 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 84.6 mt -88.12 -5.83 58.23 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.075 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.61 -19.06 55.67 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -71.41 172.01 7.69 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -62.13 143.27 94.43 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 121.654 1.569 . . . . 0.0 111.8 -178.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.456 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -92.25 155.72 17.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.173 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -107.76 47.15 0.91 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.544 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.5 pt -90.24 10.44 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.745 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 t -69.8 -126.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.377 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 10.4 tp -89.64 -39.79 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.751 0.31 . . . . 0.0 110.651 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 63.3 m-85 -43.21 150.91 0.45 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.52 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo . . . . . 0 N--CA 1.491 1.327 0 C-N-CA 122.336 2.024 . . . . 0.0 112.3 179.755 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.42 ' N ' ' CD1' ' A' ' 2' ' ' LEU . 10.8 mp 37.93 79.2 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.617 179.171 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.85 165.31 34.6 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.3 m -91.12 -12.06 36.68 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.628 0.251 . . . . 0.0 111.35 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.447 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -65.36 144.49 99.0 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.7 -179.37 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.76 -15.76 37.25 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.354 2.036 . . . . 0.0 111.785 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.506 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.6 m-85 -88.65 161.43 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.291 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -99.26 156.82 16.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.397 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.06 -91.97 0.11 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.123 -179.639 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.6 mt -132.89 -26.23 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.567 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . 0.516 ' CD2' ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.05 -3.84 58.56 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.795 -179.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.4 -10.12 71.41 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 18.0 m-85 -83.16 152.54 65.2 Favored Pre-proline 0 C--N 1.329 -0.292 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -37.45 140.08 0.24 Allowed 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.774 2.316 . . . . 0.0 111.997 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -96.77 155.17 16.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.569 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -109.89 53.35 0.69 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.608 -179.3 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 40.2 pt -91.8 -3.02 10.62 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.683 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.2 m -54.59 172.42 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.475 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -89.69 -41.12 13.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.637 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -82.2 152.4 67.9 Favored Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.383 -179.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_exo . . . . . 0 N--CA 1.49 1.318 0 C-N-CA 122.413 2.076 . . . . 0.0 112.286 179.813 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.1 p . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.113 0.482 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 36.9 77.34 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.865 178.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.18 36.33 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.185 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.4 m -97.51 -5.0 36.84 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.815 -0.226 . . . . 0.0 111.431 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -73.5 146.55 86.33 Favored Pre-proline 0 CA--C 1.539 0.546 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.747 -179.394 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -70.92 -14.56 32.51 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.479 2.12 . . . . 0.0 112.238 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.492 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.9 m-85 -88.47 155.55 19.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.794 0.33 . . . . 0.0 110.608 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -95.46 154.05 17.4 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.695 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.97 -95.87 0.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.16 -179.483 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.06 -24.14 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.558 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.7 mt -90.67 -4.72 56.56 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.808 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.89 -17.35 58.88 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -70.47 170.83 9.33 Favored Pre-proline 0 C--N 1.33 -0.265 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -62.11 142.71 93.15 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 121.878 1.719 . . . . 0.0 111.835 -178.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.492 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -93.41 153.47 18.48 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.663 -0.698 . . . . 0.0 111.198 -178.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.24 26.36 8.41 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.681 -179.408 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.436 ' O ' ' OG ' ' A' ' 5' ' ' SER . 36.2 pt -89.06 136.97 22.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.122 0.487 . . . . 0.0 110.734 -179.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.0 m -143.78 -170.01 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 -179.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 30.4 mm -87.8 -21.8 7.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.413 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.453 ' N ' ' CD1' ' A' ' 20' ' ' TYR . 0.1 OUTLIER -135.4 63.79 56.5 Favored Pre-proline 0 N--CA 1.468 0.435 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.287 -179.773 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo . . . . . 0 C--N 1.306 -1.69 0 C-N-CA 122.632 2.221 . . . . 0.0 111.998 -179.724 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.0 p . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.75 0.309 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 41.38 77.55 0.06 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.214 0.531 . . . . 0.0 111.44 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -166.04 175.51 41.57 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.4 m -113.17 -1.94 14.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.449 0.166 . . . . 0.0 110.726 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' A' ' 17' ' ' ILE . 3.5 t -66.52 134.06 94.38 Favored Pre-proline 0 CA--C 1.538 0.487 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.736 -179.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -47.65 -31.08 13.59 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 121.794 1.663 . . . . 0.0 112.516 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.564 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.1 161.94 17.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.197 -178.845 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -100.59 170.28 8.48 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.19 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.0 OUTLIER -89.83 -87.23 0.18 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.192 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 18.0 pt -146.36 -18.64 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.655 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.1 mt -89.0 -1.73 58.25 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.862 0.363 . . . . 0.0 110.03 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.42 -13.76 66.84 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 36.1 m-85 -81.48 154.43 71.43 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -49.55 128.8 21.72 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 121.969 1.779 . . . . 0.0 112.112 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -83.48 162.49 20.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.618 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -103.16 40.58 1.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.585 -179.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.44 ' O ' ' OG ' ' A' ' 5' ' ' SER . 96.9 mt -89.61 92.32 3.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.405 179.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.39 -74.76 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.16 179.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.468 ' CG2' ' N ' ' A' ' 20' ' ' TYR . 10.3 tp -133.2 -46.01 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.643 179.771 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.468 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 32.4 p90 -91.0 146.42 33.66 Favored Pre-proline 0 N--CA 1.466 0.338 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.773 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo . . . . . 0 N--CA 1.495 1.561 0 C-N-CA 122.162 1.908 . . . . 0.0 111.71 179.868 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.975 0.417 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.602 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.3 mp 37.24 81.58 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.533 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.55 168.34 35.38 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.8 m -93.07 -17.62 23.61 Favored 'General case' 0 N--CA 1.466 0.325 0 O-C-N 122.664 -0.315 . . . . 0.0 110.929 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.57 145.03 78.13 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.773 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.41 -19.54 37.66 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.535 2.157 . . . . 0.0 112.178 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -88.86 166.08 14.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.843 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.552 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 9.8 p30 -101.53 159.67 15.1 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.282 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.479 ' N ' ' HB2' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -91.1 -93.9 0.13 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.564 179.597 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.51 -24.85 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.444 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.547 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.08 -0.99 57.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.359 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.73 -9.85 72.35 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -82.71 152.8 67.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -41.88 118.25 0.88 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 122.458 2.106 . . . . 0.0 111.99 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.552 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -75.09 159.53 31.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.969 179.613 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.493 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.465 0.301 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.206 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.003 0.43 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.648 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.1 mp 38.07 79.14 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.72 178.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.28 -177.27 33.22 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.1 m -111.19 -23.89 10.6 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 t -52.18 145.31 19.02 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.709 -179.257 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -68.4 -15.12 41.6 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.338 2.025 . . . . 0.0 111.905 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.465 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.5 m-85 -88.09 156.08 19.46 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.01 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -99.27 153.86 18.62 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.226 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.415 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.6 OUTLIER -88.48 -93.44 0.11 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.631 -179.737 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -131.24 -24.88 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.914 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.568 HD22 ' N ' ' A' ' 11' ' ' LEU . 2.9 mm? -89.74 -5.57 56.86 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.541 -0.463 . . . . 0.0 110.533 -179.474 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.06 -26.94 18.6 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -61.33 168.93 2.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -62.35 144.04 94.58 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 121.44 1.426 . . . . 0.0 112.025 -178.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -89.85 153.76 20.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.706 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.547 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.463 0.215 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.402 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.941 0.4 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 13.4 mt 38.85 77.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.649 178.629 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.89 169.47 35.19 Favored Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.392 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 64.3 m -98.06 -6.01 32.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.619 0.247 . . . . 0.0 111.152 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -71.59 144.59 88.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.8 -179.355 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.96 -15.84 40.43 Favored 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.195 1.93 . . . . 0.0 112.13 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.8 m-85 -88.21 160.7 17.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.382 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 -100.21 153.17 19.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.432 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.03 -96.85 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.827 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.6 pt -129.62 -21.38 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.568 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.0 mt -91.13 -2.81 57.5 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.541 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.53 53.87 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -77.83 151.11 79.26 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.228 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -36.02 139.85 0.15 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.835 2.357 . . . . 0.0 111.881 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -94.72 160.01 14.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.34 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.466 0.362 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.594 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 99.3 p . . . . . 0 CA--C 1.523 -0.081 0 CA-C-O 120.847 0.356 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.606 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.4 mp 38.19 79.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.033 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -165.67 178.69 40.37 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.2 p -107.43 -31.75 8.02 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.789 0.328 . . . . 0.0 111.345 -179.43 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 t -39.84 130.55 1.51 Allowed Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.21 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -49.21 -26.94 11.91 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.818 1.678 . . . . 0.0 112.28 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.23 161.87 16.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.076 -178.778 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.647 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 4.8 p-10 -100.68 170.9 8.04 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.455 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -91.22 -97.95 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.105 179.705 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.7 mt -131.53 -22.45 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.478 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.7 mt -87.24 -4.21 59.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.901 0.382 . . . . 0.0 110.409 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -15.56 63.07 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 16.8 m-85 -75.77 158.21 83.04 Favored Pre-proline 0 C--N 1.328 -0.368 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.99 132.49 47.72 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.558 1.506 . . . . 0.0 111.74 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.647 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -87.52 160.18 18.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.692 -179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.513 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.642 -179.035 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.4 p . . . . . 0 N--CA 1.455 -0.207 0 CA-C-O 120.714 0.292 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.5 mt 41.12 60.97 1.88 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.143 0.497 . . . . 0.0 111.026 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.51 -169.48 14.87 Favored Glycine 0 CA--C 1.521 0.459 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.2 m -136.77 0.63 2.46 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.789 0.328 . . . . 0.0 110.485 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 5.5 t -66.43 142.84 97.94 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.714 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -45.91 -38.53 18.37 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.887 1.725 . . . . 0.0 112.294 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.489 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 4.3 m-85 -88.61 163.96 15.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.318 -179.273 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.613 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 82.2 m-20 -101.56 171.19 7.71 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.186 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -89.65 -94.54 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.393 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.7 -23.71 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 29.1 mt -86.36 -2.03 58.06 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.3 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.37 -12.78 68.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -82.08 150.66 65.33 Favored Pre-proline 0 C--N 1.33 -0.279 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -40.61 133.94 2.32 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 122.597 2.198 . . . . 0.0 112.049 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.613 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -88.15 161.16 17.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.027 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.383 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.864 0.364 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.409 ' O ' HD22 ' A' ' 16' ' ' LEU . 10.9 mt 41.86 66.32 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.746 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.48 -171.35 17.25 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.6 m -130.2 -3.94 4.42 Favored 'General case' 0 C--N 1.331 -0.207 0 O-C-N 122.752 -0.263 . . . . 0.0 110.512 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.1 t -66.46 140.19 96.49 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.734 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -45.74 -37.24 15.84 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.64 2.227 . . . . 0.0 112.25 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.492 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.1 m-85 -89.42 164.35 14.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.495 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.626 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 71.7 m-80 -101.36 173.13 6.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.982 0.42 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.42 -81.9 0.25 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.334 179.749 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.6 pt -148.46 -36.6 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.49 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 75.5 mt -66.76 -40.95 88.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.654 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.48 -27.6 2.36 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -72.44 156.83 89.96 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.621 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -49.38 138.49 30.27 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.332 2.021 . . . . 0.0 112.192 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.626 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -85.27 164.0 18.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.409 HD22 ' O ' ' A' ' 2' ' ' LEU . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.282 179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.827 0.346 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.5 mt 39.67 79.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.216 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.19 39.25 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.9 m -106.0 -25.86 11.91 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.893 0.378 . . . . 0.0 110.562 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.416 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.3 OUTLIER -48.08 145.4 5.07 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.661 -179.355 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -68.79 -18.99 41.58 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.528 2.152 . . . . 0.0 112.18 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.468 ' O ' ' N ' ' A' ' 15' ' ' ALA . 91.2 m-85 -88.61 156.93 18.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.479 ' OD1' ' N ' ' A' ' 8' ' ' ASN . 3.1 p-10 -96.27 155.77 16.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.915 0.388 . . . . 0.0 110.283 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.55 -92.01 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.392 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.8 mt -132.56 -25.68 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.529 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 66.8 mt -88.84 -1.55 58.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.538 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.69 -11.4 68.69 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -82.04 150.69 65.54 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.833 0.349 . . . . 0.0 110.356 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -36.76 132.53 0.4 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.736 2.291 . . . . 0.0 111.893 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.468 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -87.4 157.14 19.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.972 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.511 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.4 OUTLIER . . . . . 0 C--N 1.324 -0.509 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.276 -179.601 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 75.6 p . . . . . 0 N--CA 1.457 -0.12 0 CA-C-O 120.994 0.426 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.4 mt 41.58 67.98 0.5 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.521 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.3 -166.28 14.82 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.2 m -134.72 -0.33 2.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.768 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.48 ' N ' ' O ' ' A' ' 15' ' ' ALA . 5.7 t -64.21 141.79 98.17 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.686 -179.337 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -46.56 -39.4 22.77 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 121.914 1.743 . . . . 0.0 112.739 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.479 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 6.7 m-85 -89.05 167.95 12.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.384 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.541 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 49.0 m-20 -100.76 171.04 7.93 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.535 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.0 OUTLIER -88.13 -92.4 0.11 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.061 -179.698 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 97.0 mt -134.67 -39.47 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.874 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.9 mt -67.49 -39.91 85.23 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.44 -24.2 3.08 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -68.76 158.96 84.32 Favored Pre-proline 0 C--N 1.33 -0.244 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.31 130.72 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.017 1.811 . . . . 0.0 112.125 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.541 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -74.95 152.25 38.8 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.53 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.382 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.788 0.328 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.591 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.4 mp 37.47 78.73 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.282 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.11 170.82 34.97 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 t -88.59 -40.74 13.14 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.082 0.468 . . . . 0.0 110.771 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.6 OUTLIER -40.51 143.65 0.65 Allowed Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.183 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -71.85 -12.99 29.14 Favored 'Trans proline' 0 N--CA 1.498 1.74 0 C-N-CA 122.353 2.035 . . . . 0.0 111.846 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.8 m-85 -88.38 161.82 16.87 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.413 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.419 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 98.9 m-20 -98.26 156.16 16.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.237 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.524 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.82 -99.03 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.411 179.75 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.3 pt -128.63 -19.77 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.598 -0.274 . . . . 0.0 110.504 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.3 mt -91.87 -5.42 53.35 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 120.544 -0.463 . . . . 0.0 110.303 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.419 ' O ' ' ND2' ' A' ' 8' ' ' ASN . . . 94.86 -8.88 70.78 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.427 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 8.9 m-85 -86.05 153.7 57.31 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.825 0.345 . . . . 0.0 110.154 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -37.23 141.49 0.18 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 123.0 2.466 . . . . 0.0 112.0 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -99.45 155.32 17.62 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.703 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.424 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.464 0.264 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.483 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 84.0 p . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.909 0.385 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.587 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.3 mp 38.04 72.14 0.13 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.135 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.61 -167.42 19.37 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.6 m -135.58 1.3 2.83 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.704 0.288 . . . . 0.0 110.847 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 7.0 t -66.96 144.6 98.62 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.028 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -51.06 -34.94 49.15 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 121.806 1.671 . . . . 0.0 112.075 178.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.46 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 15.7 m-85 -88.04 160.29 17.91 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.065 -178.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.486 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 86.9 m-20 -100.25 164.64 11.86 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.285 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.69 -96.88 0.09 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.459 -179.385 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.59 -24.41 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.78 0.324 . . . . 0.0 110.486 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.53 -5.43 58.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.906 0.384 . . . . 0.0 110.285 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.486 ' O ' ' ND2' ' A' ' 8' ' ' ASN . . . 93.44 -9.19 74.49 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.48 160.92 71.58 Favored Pre-proline 0 C--N 1.33 -0.245 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.99 134.57 56.13 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.755 1.637 . . . . 0.0 111.795 -179.262 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.421 ' O ' ' CB ' ' A' ' 5' ' ' SER . . . -86.15 156.33 20.39 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.454 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.537 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 38.1 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.889 0.376 . . . . 0.0 110.638 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.9 mt 39.6 78.03 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.519 178.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -162.9 176.52 39.17 Favored Glycine 0 CA--C 1.529 0.934 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.216 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.3 m -107.93 -9.98 15.6 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.545 0.212 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.431 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -65.34 146.23 98.98 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.57 -179.502 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.2 -16.0 39.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 122.477 2.118 . . . . 0.0 112.264 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.7 m-85 -88.23 154.44 20.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.181 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -96.49 152.6 18.47 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.172 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.16 -92.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.207 -179.725 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.73 -24.85 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.632 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 mt -90.13 -2.68 58.11 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.763 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.8 -21.13 37.95 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.2 m-85 -70.78 154.29 94.38 Favored Pre-proline 0 C--N 1.329 -0.322 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -44.55 136.88 8.77 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.072 1.848 . . . . 0.0 112.065 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -88.52 156.62 18.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.53 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.541 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.31 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 120.781 0.324 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.603 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.2 mp 35.75 79.74 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.534 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.69 176.38 35.59 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.6 m -105.43 -3.3 22.74 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.625 0.25 . . . . 0.0 111.091 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 1.1 t -74.94 145.36 81.07 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.554 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.34 -15.1 38.45 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.293 1.996 . . . . 0.0 111.801 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.456 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.6 m-85 -88.41 161.07 17.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.35 -179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -100.06 153.21 19.4 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.836 0.35 . . . . 0.0 110.604 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.2 OUTLIER -88.0 -84.46 0.2 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.84 -179.781 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 15.6 pt -143.69 -23.03 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.645 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 84.6 mt -88.12 -5.83 58.23 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.075 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.61 -19.06 55.67 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -71.41 172.01 7.69 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.099 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -62.13 143.27 94.43 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 121.654 1.569 . . . . 0.0 111.8 -178.507 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.456 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -92.25 155.72 17.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.173 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.482 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.466 0.368 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.544 -179.244 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.588 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.8 mp 37.93 79.2 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.617 179.171 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.85 165.31 34.6 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.3 m -91.12 -12.06 36.68 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.628 0.251 . . . . 0.0 111.35 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.447 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -65.36 144.49 99.0 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.7 -179.37 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.76 -15.76 37.25 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.354 2.036 . . . . 0.0 111.785 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.506 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.6 m-85 -88.65 161.43 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.291 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -99.26 156.82 16.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.397 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.06 -91.97 0.11 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.123 -179.639 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.6 mt -132.89 -26.23 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.567 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LEU . . . . . 0.563 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.05 -3.84 58.56 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.795 -179.721 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.4 -10.12 71.41 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 18.0 m-85 -83.16 152.54 65.2 Favored Pre-proline 0 C--N 1.329 -0.292 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -37.45 140.08 0.24 Allowed 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.774 2.316 . . . . 0.0 111.997 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -96.77 155.17 16.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.569 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.433 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.464 0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.608 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.1 p . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.113 0.482 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 36.9 77.34 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.865 178.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.18 36.33 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.185 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.4 m -97.51 -5.0 36.84 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.815 -0.226 . . . . 0.0 111.431 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -73.5 146.55 86.33 Favored Pre-proline 0 CA--C 1.539 0.546 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.747 -179.394 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -70.92 -14.56 32.51 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.479 2.12 . . . . 0.0 112.238 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.492 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.9 m-85 -88.47 155.55 19.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.794 0.33 . . . . 0.0 110.608 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -95.46 154.05 17.4 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.695 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.97 -95.87 0.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.16 -179.483 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.06 -24.14 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.558 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.7 mt -90.67 -4.72 56.56 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.808 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.89 -17.35 58.88 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -70.47 170.83 9.33 Favored Pre-proline 0 C--N 1.33 -0.265 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -62.11 142.71 93.15 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 121.878 1.719 . . . . 0.0 111.835 -178.601 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.492 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -93.41 153.47 18.48 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.663 -0.698 . . . . 0.0 111.198 -178.701 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.513 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.681 -179.408 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.0 p . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.75 0.309 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 41.38 77.55 0.06 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.214 0.531 . . . . 0.0 111.44 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -166.04 175.51 41.57 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.4 m -113.17 -1.94 14.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.449 0.166 . . . . 0.0 110.726 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.5 t -66.52 134.06 94.38 Favored Pre-proline 0 CA--C 1.538 0.487 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.736 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -47.65 -31.08 13.59 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 121.794 1.663 . . . . 0.0 112.516 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TYR . . . . . 0.564 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.1 161.94 17.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.197 -178.845 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.657 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 8.4 p30 -100.59 170.28 8.48 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.19 179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.519 ' N ' ' HB2' ' A' ' 15' ' ' ALA . 0.0 OUTLIER -89.83 -87.23 0.18 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.192 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.414 HG21 HD13 ' A' ' 10' ' ' ILE . 18.0 pt -146.36 -18.64 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.655 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.1 mt -89.0 -1.73 58.25 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.862 0.363 . . . . 0.0 110.03 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.42 -13.76 66.84 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 36.1 m-85 -81.48 154.43 71.43 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -49.55 128.8 21.72 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 121.969 1.779 . . . . 0.0 112.112 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.657 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -83.48 162.49 20.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.618 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.484 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.585 -179.205 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.975 0.417 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.602 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.3 mp 37.24 81.58 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.533 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.55 168.34 35.38 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.8 m -93.07 -17.62 23.61 Favored 'General case' 0 N--CA 1.466 0.325 0 O-C-N 122.664 -0.315 . . . . 0.0 110.929 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.57 145.03 78.13 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.773 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.41 -19.54 37.66 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.535 2.157 . . . . 0.0 112.178 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -88.86 166.08 14.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.843 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.552 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 9.8 p30 -101.53 159.67 15.1 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.282 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.479 ' N ' ' HB2' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -91.1 -93.9 0.13 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.564 179.597 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.51 -24.85 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.444 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.547 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.08 -0.99 57.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.359 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.73 -9.85 72.35 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -82.71 152.8 67.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -41.88 118.25 0.88 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 122.458 2.106 . . . . 0.0 111.99 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.552 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -75.09 159.53 31.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.969 179.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.493 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -103.17 46.37 0.92 Allowed 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.206 -179.446 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 89.3 mt -89.69 111.1 22.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 179.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -139.63 168.09 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.284 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.443 ' O ' HG22 ' A' ' 19' ' ' ILE . 96.3 mt -87.32 -13.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.556 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -143.01 149.55 49.63 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.514 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.491 1.372 0 C-N-CA 122.366 2.044 . . . . 0.0 111.963 179.76 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.003 0.43 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.648 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.1 mp 38.07 79.14 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.72 178.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.28 -177.27 33.22 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.1 m -111.19 -23.89 10.6 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.506 ' HB2' ' H ' ' A' ' 17' ' ' ILE . 1.3 t -52.18 145.31 19.02 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.709 -179.257 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -68.4 -15.12 41.6 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.338 2.025 . . . . 0.0 111.905 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.465 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.5 m-85 -88.09 156.08 19.46 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.01 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 85.5 m-20 -99.27 153.86 18.62 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.226 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.415 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.6 OUTLIER -88.48 -93.44 0.11 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.631 -179.737 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -131.24 -24.88 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.914 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.568 HD22 ' N ' ' A' ' 11' ' ' LEU . 2.9 mm? -89.74 -5.57 56.86 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.541 -0.463 . . . . 0.0 110.533 -179.474 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.06 -26.94 18.6 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -61.33 168.93 2.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -62.35 144.04 94.58 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 121.44 1.426 . . . . 0.0 112.025 -178.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -89.85 153.76 20.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.706 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.547 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER -103.55 59.0 0.74 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.402 -179.353 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.506 ' H ' ' HB2' ' A' ' 5' ' ' SER . 97.4 mt -89.02 -40.13 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.469 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -88.71 27.45 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 110.429 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 21.1 tt -89.16 -15.04 9.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.63 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 50.79 76.54 0.53 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.405 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_exo . . . . . 0 C--N 1.308 -1.559 0 C-N-CA 122.629 2.219 . . . . 0.0 112.17 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.941 0.4 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 13.4 mt 38.85 77.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.649 178.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.89 169.47 35.19 Favored Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.392 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 64.3 m -98.06 -6.01 32.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.619 0.247 . . . . 0.0 111.152 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -71.59 144.59 88.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.8 -179.355 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.96 -15.84 40.43 Favored 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.195 1.93 . . . . 0.0 112.13 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.8 m-85 -88.21 160.7 17.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.382 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 -100.21 153.17 19.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.432 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.03 -96.85 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.827 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.6 pt -129.62 -21.38 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.568 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.0 mt -91.13 -2.81 57.5 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.541 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.53 53.87 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -77.83 151.11 79.26 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.228 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -36.02 139.85 0.15 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.835 2.357 . . . . 0.0 111.881 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -94.72 160.01 14.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.34 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.57 51.17 0.8 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.594 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 40.8 pt -89.33 12.3 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.547 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 19' ' ' ILE . 1.4 t -77.48 -148.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.105 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.529 ' H ' HG12 ' A' ' 18' ' ' VAL . 96.4 mt -89.83 -39.53 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.683 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -43.25 147.96 0.68 Allowed Pre-proline 0 CA--C 1.534 0.357 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.661 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo . . . . . 0 N--CA 1.49 1.296 0 C-N-CA 122.29 1.993 . . . . 0.0 111.995 179.639 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 99.3 p . . . . . 0 CA--C 1.523 -0.081 0 CA-C-O 120.847 0.356 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.606 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.4 mp 38.19 79.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.033 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -165.67 178.69 40.37 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.2 p -107.43 -31.75 8.02 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.789 0.328 . . . . 0.0 111.345 -179.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 t -39.84 130.55 1.51 Allowed Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.21 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -49.21 -26.94 11.91 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.818 1.678 . . . . 0.0 112.28 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.23 161.87 16.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.076 -178.778 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.647 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 4.8 p-10 -100.68 170.9 8.04 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.455 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -91.22 -97.95 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.105 179.705 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.7 mt -131.53 -22.45 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.478 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.7 mt -87.24 -4.21 59.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.901 0.382 . . . . 0.0 110.409 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -15.56 63.07 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 16.8 m-85 -75.77 158.21 83.04 Favored Pre-proline 0 C--N 1.328 -0.368 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.99 132.49 47.72 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.558 1.506 . . . . 0.0 111.74 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.647 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -87.52 160.18 18.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.692 -179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.513 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -103.02 41.71 1.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.642 -179.035 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.8 mt -89.85 124.92 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.463 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -124.7 -94.44 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.415 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.9 mt -136.16 -36.41 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.585 ' N ' ' CD ' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -78.5 -43.55 2.01 Favored Pre-proline 0 CA--C 1.533 0.326 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.298 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 20' ' ' TYR . 52.1 Cg_exo . . . . . 0 N--CA 1.496 1.622 0 C-N-CA 122.495 2.13 . . . . 0.0 112.16 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.4 p . . . . . 0 N--CA 1.455 -0.207 0 CA-C-O 120.714 0.292 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.5 mt 41.12 60.97 1.88 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.143 0.497 . . . . 0.0 111.026 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.51 -169.48 14.87 Favored Glycine 0 CA--C 1.521 0.459 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.2 m -136.77 0.63 2.46 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.789 0.328 . . . . 0.0 110.485 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 5.5 t -66.43 142.84 97.94 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.714 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -45.91 -38.53 18.37 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.887 1.725 . . . . 0.0 112.294 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.489 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 4.3 m-85 -88.61 163.96 15.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.318 -179.273 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.613 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 82.2 m-20 -101.56 171.19 7.71 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.186 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -89.65 -94.54 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.393 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.7 -23.71 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 29.1 mt -86.36 -2.03 58.06 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.3 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.37 -12.78 68.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -82.08 150.66 65.33 Favored Pre-proline 0 C--N 1.33 -0.279 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -40.61 133.94 2.32 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 122.597 2.198 . . . . 0.0 112.049 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.613 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -88.15 161.16 17.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.027 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.24 62.12 0.69 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.383 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.5 pt -89.28 17.88 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.524 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.2 m -74.98 159.34 5.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.388 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.452 HG23 ' N ' ' A' ' 20' ' ' TYR . 20.9 tt -88.06 -38.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.591 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.452 ' N ' HG23 ' A' ' 19' ' ' ILE . 2.6 p90 -86.48 151.35 53.18 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.485 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo . . . . . 0 C--N 1.313 -1.319 0 C-N-CA 122.495 2.13 . . . . 0.0 111.994 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.864 0.364 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.409 ' O ' HD22 ' A' ' 16' ' ' LEU . 10.9 mt 41.86 66.32 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.746 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.48 -171.35 17.25 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.6 m -130.2 -3.94 4.42 Favored 'General case' 0 C--N 1.331 -0.207 0 O-C-N 122.752 -0.263 . . . . 0.0 110.512 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.406 ' OG ' ' CG1' ' A' ' 17' ' ' ILE . 6.1 t -66.46 140.19 96.49 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.734 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -45.74 -37.24 15.84 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.64 2.227 . . . . 0.0 112.25 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.492 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.1 m-85 -89.42 164.35 14.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.495 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.626 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 71.7 m-80 -101.36 173.13 6.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.982 0.42 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.42 -81.9 0.25 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.334 179.749 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.6 pt -148.46 -36.6 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.49 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 75.5 mt -66.76 -40.95 88.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.654 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.48 -27.6 2.36 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -72.44 156.83 89.96 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.621 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -49.38 138.49 30.27 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.332 2.021 . . . . 0.0 112.192 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.626 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -85.27 164.0 18.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.409 HD22 ' O ' ' A' ' 2' ' ' LEU . 0.4 OUTLIER -118.64 67.16 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.282 179.827 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.406 ' CG1' ' OG ' ' A' ' 5' ' ' SER . 5.7 pt -88.9 115.47 28.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.299 0.571 . . . . 0.0 110.385 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.641 HG22 ' H ' ' A' ' 20' ' ' TYR . 3.2 p -142.66 141.73 27.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.412 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.0 mt -89.72 -17.67 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.769 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.641 ' H ' HG22 ' A' ' 18' ' ' VAL . 13.5 p90 -124.92 80.0 63.96 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.085 0.469 . . . . 0.0 110.476 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo . . . . . 0 C--N 1.307 -1.643 0 C-N-CA 122.741 2.294 . . . . 0.0 112.073 -179.918 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.827 0.346 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.5 mt 39.67 79.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.216 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.19 39.25 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.9 m -106.0 -25.86 11.91 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.893 0.378 . . . . 0.0 110.562 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.416 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.3 OUTLIER -48.08 145.4 5.07 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.661 -179.355 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -68.79 -18.99 41.58 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.528 2.152 . . . . 0.0 112.18 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.468 ' O ' ' N ' ' A' ' 15' ' ' ALA . 91.2 m-85 -88.61 156.93 18.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.479 ' OD1' ' N ' ' A' ' 8' ' ' ASN . 3.1 p-10 -96.27 155.77 16.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.915 0.388 . . . . 0.0 110.283 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.55 -92.01 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.392 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.8 mt -132.56 -25.68 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.529 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 66.8 mt -88.84 -1.55 58.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.538 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.69 -11.4 68.69 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -82.04 150.69 65.54 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.833 0.349 . . . . 0.0 110.356 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -36.76 132.53 0.4 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.736 2.291 . . . . 0.0 111.893 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.468 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -87.4 157.14 19.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.972 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.511 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.4 OUTLIER -100.74 39.41 1.38 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.276 -179.601 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -89.24 124.44 41.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.252 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.7 t -140.12 -90.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.774 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 19.8 tt -96.95 -13.89 7.95 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-O 120.762 0.315 . . . . 0.0 110.336 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.447 ' CD1' ' C ' ' A' ' 20' ' ' TYR . 19.4 p90 -141.69 146.31 40.83 Favored Pre-proline 0 CA--C 1.536 0.424 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo . . . . . 0 N--CA 1.496 1.621 0 C-N-CA 122.448 2.099 . . . . 0.0 111.855 179.191 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 75.6 p . . . . . 0 N--CA 1.457 -0.12 0 CA-C-O 120.994 0.426 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.4 mt 41.58 67.98 0.5 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.521 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.3 -166.28 14.82 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.2 m -134.72 -0.33 2.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.768 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.48 ' N ' ' O ' ' A' ' 15' ' ' ALA . 5.7 t -64.21 141.79 98.17 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.686 -179.337 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -46.56 -39.4 22.77 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 121.914 1.743 . . . . 0.0 112.739 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.479 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 6.7 m-85 -89.05 167.95 12.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.384 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.541 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 49.0 m-20 -100.76 171.04 7.93 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.535 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.0 OUTLIER -88.13 -92.4 0.11 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.061 -179.698 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 97.0 mt -134.67 -39.47 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.874 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.9 mt -67.49 -39.91 85.23 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.44 -24.2 3.08 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -68.76 158.96 84.32 Favored Pre-proline 0 C--N 1.33 -0.244 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -51.31 130.72 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.017 1.811 . . . . 0.0 112.125 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.541 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -74.95 152.25 38.8 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.53 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.3 OUTLIER -96.57 35.86 1.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.382 -179.726 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -92.68 113.49 27.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.269 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.0 t -146.83 -80.99 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.12 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -93.03 -50.11 12.45 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.572 -0.285 . . . . 0.0 110.825 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.405 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.7 p90 -102.25 151.23 38.08 Favored Pre-proline 0 N--CA 1.467 0.414 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo . . . . . 0 N--CA 1.493 1.472 0 C-N-CA 122.541 2.16 . . . . 0.0 111.762 179.54 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.788 0.328 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.591 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.4 mp 37.47 78.73 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.282 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.11 170.82 34.97 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 t -88.59 -40.74 13.14 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.082 0.468 . . . . 0.0 110.771 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.6 OUTLIER -40.51 143.65 0.65 Allowed Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.183 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -71.85 -12.99 29.14 Favored 'Trans proline' 0 N--CA 1.498 1.74 0 C-N-CA 122.353 2.035 . . . . 0.0 111.846 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.8 m-85 -88.38 161.82 16.87 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.413 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.419 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 98.9 m-20 -98.26 156.16 16.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.237 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.524 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.82 -99.03 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.411 179.75 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.3 pt -128.63 -19.77 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.598 -0.274 . . . . 0.0 110.504 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.3 mt -91.87 -5.42 53.35 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 120.544 -0.463 . . . . 0.0 110.303 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.419 ' O ' ' ND2' ' A' ' 8' ' ' ASN . . . 94.86 -8.88 70.78 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.427 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 8.9 m-85 -86.05 153.7 57.31 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.825 0.345 . . . . 0.0 110.154 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -37.23 141.49 0.18 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 123.0 2.466 . . . . 0.0 112.0 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -99.45 155.32 17.62 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.703 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.424 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER -110.5 51.93 0.75 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.483 -179.621 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.0 pt -90.32 5.51 5.27 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.883 0.373 . . . . 0.0 110.545 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.8 m -72.99 171.83 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 16.4 tt -87.76 -27.57 5.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.735 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -73.32 146.84 87.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.425 -179.69 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo . . . . . 0 N--CA 1.492 1.404 0 C-N-CA 122.152 1.901 . . . . 0.0 112.315 179.677 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 84.0 p . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.909 0.385 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.587 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.3 mp 38.04 72.14 0.13 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.135 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.61 -167.42 19.37 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.6 m -135.58 1.3 2.83 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.704 0.288 . . . . 0.0 110.847 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 7.0 t -66.96 144.6 98.62 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.028 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -51.06 -34.94 49.15 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 121.806 1.671 . . . . 0.0 112.075 178.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.46 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 15.7 m-85 -88.04 160.29 17.91 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.065 -178.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.486 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 86.9 m-20 -100.25 164.64 11.86 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.285 -179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.69 -96.88 0.09 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.459 -179.385 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.59 -24.41 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.78 0.324 . . . . 0.0 110.486 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.53 -5.43 58.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.906 0.384 . . . . 0.0 110.285 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.486 ' O ' ' ND2' ' A' ' 8' ' ' ASN . . . 93.44 -9.19 74.49 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.48 160.92 71.58 Favored Pre-proline 0 C--N 1.33 -0.245 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.99 134.57 56.13 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.755 1.637 . . . . 0.0 111.795 -179.262 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.421 ' O ' ' CB ' ' A' ' 5' ' ' SER . . . -86.15 156.33 20.39 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.454 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER -109.63 50.2 0.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.537 -179.833 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.8 pt -89.36 45.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.849 0.357 . . . . 0.0 110.705 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.431 ' H ' HG22 ' A' ' 18' ' ' VAL . 15.6 m -88.9 172.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.418 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.441 HG23 ' N ' ' A' ' 20' ' ' TYR . 20.4 tt -88.61 -38.13 11.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.689 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.441 ' N ' HG23 ' A' ' 19' ' ' ILE . 3.2 p90 -82.31 152.56 67.79 Favored Pre-proline 0 CA--C 1.535 0.376 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.103 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo . . . . . 0 N--CA 1.49 1.294 0 C-N-CA 122.404 2.069 . . . . 0.0 112.393 179.681 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 38.1 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.889 0.376 . . . . 0.0 110.638 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.9 mt 39.6 78.03 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.519 178.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -162.9 176.52 39.17 Favored Glycine 0 CA--C 1.529 0.934 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.216 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.3 m -107.93 -9.98 15.6 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.545 0.212 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.431 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -65.34 146.23 98.98 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.57 -179.502 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.2 -16.0 39.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 122.477 2.118 . . . . 0.0 112.264 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.7 m-85 -88.23 154.44 20.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.181 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -96.49 152.6 18.47 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.172 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.16 -92.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.207 -179.725 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.73 -24.85 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.632 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 mt -90.13 -2.68 58.11 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.763 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.8 -21.13 37.95 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.2 m-85 -70.78 154.29 94.38 Favored Pre-proline 0 C--N 1.329 -0.322 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -44.55 136.88 8.77 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.072 1.848 . . . . 0.0 112.065 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -88.52 156.62 18.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.53 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.541 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -100.58 43.59 1.05 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.31 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -89.82 117.41 33.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.226 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.8 m -137.03 167.47 23.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.226 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.9 mm -86.62 -38.86 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.865 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.571 ' O ' ' CD2' ' A' ' 20' ' ' TYR . 14.8 p90 -116.15 82.65 11.63 Favored Pre-proline 0 N--CA 1.468 0.428 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.584 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_exo . . . . . 0 C--N 1.307 -1.621 0 C-N-CA 122.296 1.998 . . . . 0.0 112.147 179.938 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 120.781 0.324 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.603 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.2 mp 35.75 79.74 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.534 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.69 176.38 35.59 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.6 m -105.43 -3.3 22.74 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.625 0.25 . . . . 0.0 111.091 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 1.1 t -74.94 145.36 81.07 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.554 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.34 -15.1 38.45 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.293 1.996 . . . . 0.0 111.801 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.456 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.6 m-85 -88.41 161.07 17.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.35 -179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -100.06 153.21 19.4 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.836 0.35 . . . . 0.0 110.604 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.2 OUTLIER -88.0 -84.46 0.2 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.84 -179.781 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 15.6 pt -143.69 -23.03 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.645 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 84.6 mt -88.12 -5.83 58.23 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.075 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.61 -19.06 55.67 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -71.41 172.01 7.69 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.099 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -62.13 143.27 94.43 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 121.654 1.569 . . . . 0.0 111.8 -178.507 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.456 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -92.25 155.72 17.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.173 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.482 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -107.76 47.15 0.91 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.544 -179.244 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.5 pt -90.24 10.44 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.745 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 t -69.8 -126.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.377 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.466 HG23 ' N ' ' A' ' 20' ' ' TYR . 10.4 tp -89.64 -39.79 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.751 0.31 . . . . 0.0 110.651 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.466 ' N ' HG23 ' A' ' 19' ' ' ILE . 63.3 m-85 -43.21 150.91 0.45 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.52 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo . . . . . 0 N--CA 1.491 1.327 0 C-N-CA 122.336 2.024 . . . . 0.0 112.3 179.755 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.588 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.8 mp 37.93 79.2 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.617 179.171 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.85 165.31 34.6 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.3 m -91.12 -12.06 36.68 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.628 0.251 . . . . 0.0 111.35 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.447 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -65.36 144.49 99.0 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.7 -179.37 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.76 -15.76 37.25 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.354 2.036 . . . . 0.0 111.785 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.506 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.6 m-85 -88.65 161.43 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.291 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -99.26 156.82 16.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.397 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.06 -91.97 0.11 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.123 -179.639 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.6 mt -132.89 -26.23 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.567 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LEU . . . . . 0.563 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.05 -3.84 58.56 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.795 -179.721 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.4 -10.12 71.41 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 18.0 m-85 -83.16 152.54 65.2 Favored Pre-proline 0 C--N 1.329 -0.292 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -37.45 140.08 0.24 Allowed 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.774 2.316 . . . . 0.0 111.997 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -96.77 155.17 16.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.569 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.433 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -109.89 53.35 0.69 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.608 -179.3 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 40.2 pt -91.8 -3.02 10.62 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.683 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.2 m -54.59 172.42 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.475 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -89.69 -41.12 13.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.637 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -82.2 152.4 67.9 Favored Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.383 -179.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_exo . . . . . 0 N--CA 1.49 1.318 0 C-N-CA 122.413 2.076 . . . . 0.0 112.286 179.813 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.1 p . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.113 0.482 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 36.9 77.34 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.865 178.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.18 36.33 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.185 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.4 m -97.51 -5.0 36.84 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.815 -0.226 . . . . 0.0 111.431 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -73.5 146.55 86.33 Favored Pre-proline 0 CA--C 1.539 0.546 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.747 -179.394 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -70.92 -14.56 32.51 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.479 2.12 . . . . 0.0 112.238 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.492 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.9 m-85 -88.47 155.55 19.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.794 0.33 . . . . 0.0 110.608 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -95.46 154.05 17.4 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.695 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.97 -95.87 0.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.16 -179.483 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.06 -24.14 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.558 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.7 mt -90.67 -4.72 56.56 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.808 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.89 -17.35 58.88 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -70.47 170.83 9.33 Favored Pre-proline 0 C--N 1.33 -0.265 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -62.11 142.71 93.15 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 121.878 1.719 . . . . 0.0 111.835 -178.601 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.492 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -93.41 153.47 18.48 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.663 -0.698 . . . . 0.0 111.198 -178.701 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.513 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -103.24 26.36 8.41 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.681 -179.408 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 pt -89.06 136.97 22.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.122 0.487 . . . . 0.0 110.734 -179.468 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.0 m -143.78 -170.01 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 -179.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 30.4 mm -87.8 -21.8 7.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.413 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.453 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 0.1 OUTLIER -135.4 63.79 56.5 Favored Pre-proline 0 N--CA 1.468 0.435 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.287 -179.773 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo . . . . . 0 C--N 1.306 -1.69 0 C-N-CA 122.632 2.221 . . . . 0.0 111.998 -179.724 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.0 p . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.75 0.309 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 41.38 77.55 0.06 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.214 0.531 . . . . 0.0 111.44 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -166.04 175.51 41.57 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.4 m -113.17 -1.94 14.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.449 0.166 . . . . 0.0 110.726 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.5 t -66.52 134.06 94.38 Favored Pre-proline 0 CA--C 1.538 0.487 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.736 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -47.65 -31.08 13.59 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 121.794 1.663 . . . . 0.0 112.516 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.564 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.1 161.94 17.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.197 -178.845 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.657 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 8.4 p30 -100.59 170.28 8.48 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.19 179.762 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.519 ' N ' ' HB2' ' A' ' 15' ' ' ALA . 0.0 OUTLIER -89.83 -87.23 0.18 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.192 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.414 HG21 HD13 ' A' ' 10' ' ' ILE . 18.0 pt -146.36 -18.64 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.655 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.1 mt -89.0 -1.73 58.25 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.862 0.363 . . . . 0.0 110.03 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.42 -13.76 66.84 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 36.1 m-85 -81.48 154.43 71.43 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -49.55 128.8 21.72 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 121.969 1.779 . . . . 0.0 112.112 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.657 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -83.48 162.49 20.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.618 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.484 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.4 OUTLIER -103.16 40.58 1.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.585 -179.205 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.9 mt -89.61 92.32 3.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.405 179.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.39 -74.76 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.16 179.649 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.578 HG23 ' N ' ' A' ' 20' ' ' TYR . 10.3 tp -133.2 -46.01 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.643 179.771 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.578 ' N ' HG23 ' A' ' 19' ' ' ILE . 32.4 p90 -91.0 146.42 33.66 Favored Pre-proline 0 N--CA 1.466 0.338 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.773 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo . . . . . 0 N--CA 1.495 1.561 0 C-N-CA 122.162 1.908 . . . . 0.0 111.71 179.868 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.975 0.417 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.602 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.3 mp 37.24 81.58 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.533 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.55 168.34 35.38 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.8 m -93.07 -17.62 23.61 Favored 'General case' 0 N--CA 1.466 0.325 0 O-C-N 122.664 -0.315 . . . . 0.0 110.929 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.57 145.03 78.13 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.773 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.41 -19.54 37.66 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.535 2.157 . . . . 0.0 112.178 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -88.86 166.08 14.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.843 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.552 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 9.8 p30 -101.53 159.67 15.1 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.282 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.479 ' N ' ' HB2' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -91.1 -93.9 0.13 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.564 179.597 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.51 -24.85 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.444 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.547 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.08 -0.99 57.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.359 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.73 -9.85 72.35 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -82.71 152.8 67.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -41.88 118.25 0.88 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 122.458 2.106 . . . . 0.0 111.99 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.552 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -75.09 159.53 31.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.969 179.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.493 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.465 0.301 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.206 -179.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.003 0.43 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.648 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.1 mp 38.07 79.14 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.72 178.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.28 -177.27 33.22 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.1 m -111.19 -23.89 10.6 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 t -52.18 145.31 19.02 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.709 -179.257 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -68.4 -15.12 41.6 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.338 2.025 . . . . 0.0 111.905 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.465 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.5 m-85 -88.09 156.08 19.46 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.01 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -99.27 153.86 18.62 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.226 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.415 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.6 OUTLIER -88.48 -93.44 0.11 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.631 -179.737 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -131.24 -24.88 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.914 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.568 HD22 ' N ' ' A' ' 11' ' ' LEU . 2.9 mm? -89.74 -5.57 56.86 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.541 -0.463 . . . . 0.0 110.533 -179.474 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.06 -26.94 18.6 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -61.33 168.93 2.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -62.35 144.04 94.58 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 121.44 1.426 . . . . 0.0 112.025 -178.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -89.85 153.76 20.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.706 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.547 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.463 0.215 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.402 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.941 0.4 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 13.4 mt 38.85 77.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.649 178.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.89 169.47 35.19 Favored Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.392 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 64.3 m -98.06 -6.01 32.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.619 0.247 . . . . 0.0 111.152 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -71.59 144.59 88.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.8 -179.355 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.96 -15.84 40.43 Favored 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.195 1.93 . . . . 0.0 112.13 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.8 m-85 -88.21 160.7 17.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.382 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -100.21 153.17 19.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.432 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.03 -96.85 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.827 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.6 pt -129.62 -21.38 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.568 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.0 mt -91.13 -2.81 57.5 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.541 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.53 53.87 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -77.83 151.11 79.26 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.228 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -36.02 139.85 0.15 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.835 2.357 . . . . 0.0 111.881 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -94.72 160.01 14.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.34 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.466 0.362 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.594 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 99.3 p . . . . . 0 CA--C 1.523 -0.081 0 CA-C-O 120.847 0.356 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.606 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.4 mp 38.19 79.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.033 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -165.67 178.69 40.37 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.2 p -107.43 -31.75 8.02 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.789 0.328 . . . . 0.0 111.345 -179.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 t -39.84 130.55 1.51 Allowed Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.21 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -49.21 -26.94 11.91 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.818 1.678 . . . . 0.0 112.28 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.23 161.87 16.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.076 -178.778 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.647 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 4.8 p-10 -100.68 170.9 8.04 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.455 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -91.22 -97.95 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.105 179.705 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.7 mt -131.53 -22.45 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.478 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.7 mt -87.24 -4.21 59.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.901 0.382 . . . . 0.0 110.409 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -15.56 63.07 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 16.8 m-85 -75.77 158.21 83.04 Favored Pre-proline 0 C--N 1.328 -0.368 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.99 132.49 47.72 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.558 1.506 . . . . 0.0 111.74 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.647 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -87.52 160.18 18.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.692 -179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.513 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--N 1.33 -0.248 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.642 -179.035 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.4 p . . . . . 0 N--CA 1.455 -0.207 0 CA-C-O 120.714 0.292 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.5 mt 41.12 60.97 1.88 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.143 0.497 . . . . 0.0 111.026 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.51 -169.48 14.87 Favored Glycine 0 CA--C 1.521 0.459 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.2 m -136.77 0.63 2.46 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.789 0.328 . . . . 0.0 110.485 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 5.5 t -66.43 142.84 97.94 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.714 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -45.91 -38.53 18.37 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.887 1.725 . . . . 0.0 112.294 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.489 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 4.3 m-85 -88.61 163.96 15.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.318 -179.273 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.613 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 82.2 m-20 -101.56 171.19 7.71 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.186 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -89.65 -94.54 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.393 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.7 -23.71 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 29.1 mt -86.36 -2.03 58.06 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.3 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.37 -12.78 68.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -82.08 150.66 65.33 Favored Pre-proline 0 C--N 1.33 -0.279 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -40.61 133.94 2.32 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 122.597 2.198 . . . . 0.0 112.049 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.613 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -88.15 161.16 17.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.027 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.327 -0.391 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.383 179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.864 0.364 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.409 ' O ' HD22 ' A' ' 16' ' ' LEU . 10.9 mt 41.86 66.32 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.746 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.48 -171.35 17.25 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.6 m -130.2 -3.94 4.42 Favored 'General case' 0 C--N 1.331 -0.207 0 O-C-N 122.752 -0.263 . . . . 0.0 110.512 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.1 t -66.46 140.19 96.49 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.734 -179.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -45.74 -37.24 15.84 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.64 2.227 . . . . 0.0 112.25 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.492 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.1 m-85 -89.42 164.35 14.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.495 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.626 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 71.7 m-80 -101.36 173.13 6.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.982 0.42 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.42 -81.9 0.25 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.334 179.749 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.6 pt -148.46 -36.6 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.49 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 75.5 mt -66.76 -40.95 88.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.654 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.48 -27.6 2.36 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -72.44 156.83 89.96 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.621 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -49.38 138.49 30.27 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.332 2.021 . . . . 0.0 112.192 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.626 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -85.27 164.0 18.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.409 HD22 ' O ' ' A' ' 2' ' ' LEU . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.282 179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.827 0.346 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.5 mt 39.67 79.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.216 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.19 39.25 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.9 m -106.0 -25.86 11.91 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.893 0.378 . . . . 0.0 110.562 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.416 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.3 OUTLIER -48.08 145.4 5.07 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.661 -179.355 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -68.79 -18.99 41.58 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.528 2.152 . . . . 0.0 112.18 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.468 ' O ' ' N ' ' A' ' 15' ' ' ALA . 91.2 m-85 -88.61 156.93 18.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.479 ' OD1' ' N ' ' A' ' 8' ' ' ASN . 3.1 p-10 -96.27 155.77 16.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.915 0.388 . . . . 0.0 110.283 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.55 -92.01 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.392 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.8 mt -132.56 -25.68 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.529 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 66.8 mt -88.84 -1.55 58.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.538 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.69 -11.4 68.69 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -82.04 150.69 65.54 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.833 0.349 . . . . 0.0 110.356 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -36.76 132.53 0.4 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.736 2.291 . . . . 0.0 111.893 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.468 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -87.4 157.14 19.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.972 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.511 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.4 OUTLIER . . . . . 0 C--N 1.324 -0.509 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.276 -179.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 75.6 p . . . . . 0 N--CA 1.457 -0.12 0 CA-C-O 120.994 0.426 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.4 mt 41.58 67.98 0.5 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.521 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.3 -166.28 14.82 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.2 m -134.72 -0.33 2.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.768 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.48 ' N ' ' O ' ' A' ' 15' ' ' ALA . 5.7 t -64.21 141.79 98.17 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.686 -179.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -46.56 -39.4 22.77 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 121.914 1.743 . . . . 0.0 112.739 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.479 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 6.7 m-85 -89.05 167.95 12.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.384 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.541 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 8.8 m120 -100.76 171.04 7.93 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.535 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.0 OUTLIER -88.13 -92.4 0.11 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.061 -179.698 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 97.0 mt -134.67 -39.47 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.874 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.9 mt -67.49 -39.91 85.23 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.44 -24.2 3.08 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -68.76 158.96 84.32 Favored Pre-proline 0 C--N 1.33 -0.244 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.419 ' HA ' HD22 ' A' ' 8' ' ' ASN . 51.1 Cg_exo -51.31 130.72 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.017 1.811 . . . . 0.0 112.125 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.541 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -74.95 152.25 38.8 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.53 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.382 -179.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.788 0.328 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.591 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.4 mp 37.47 78.73 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.282 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.11 170.82 34.97 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 t -88.59 -40.74 13.14 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.082 0.468 . . . . 0.0 110.771 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.6 OUTLIER -40.51 143.65 0.65 Allowed Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.183 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -71.85 -12.99 29.14 Favored 'Trans proline' 0 N--CA 1.498 1.74 0 C-N-CA 122.353 2.035 . . . . 0.0 111.846 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.8 m-85 -88.38 161.82 16.87 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.413 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.419 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 98.9 m-20 -98.26 156.16 16.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.237 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.524 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.82 -99.03 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.411 179.75 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.3 pt -128.63 -19.77 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.598 -0.274 . . . . 0.0 110.504 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.3 mt -91.87 -5.42 53.35 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 120.544 -0.463 . . . . 0.0 110.303 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.419 ' O ' ' ND2' ' A' ' 8' ' ' ASN . . . 94.86 -8.88 70.78 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.427 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 8.9 m-85 -86.05 153.7 57.31 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.825 0.345 . . . . 0.0 110.154 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -37.23 141.49 0.18 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 123.0 2.466 . . . . 0.0 112.0 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -99.45 155.32 17.62 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.703 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.424 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 N--CA 1.464 0.264 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.483 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 84.0 p . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.909 0.385 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.587 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.3 mp 38.04 72.14 0.13 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.135 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.61 -167.42 19.37 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.6 m -135.58 1.3 2.83 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.704 0.288 . . . . 0.0 110.847 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 7.0 t -66.96 144.6 98.62 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.028 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -51.06 -34.94 49.15 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 121.806 1.671 . . . . 0.0 112.075 178.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.46 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 15.7 m-85 -88.04 160.29 17.91 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.065 -178.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -100.25 164.64 11.86 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.285 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.69 -96.88 0.09 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.459 -179.385 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.59 -24.41 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.78 0.324 . . . . 0.0 110.486 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.53 -5.43 58.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.906 0.384 . . . . 0.0 110.285 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.44 -9.19 74.49 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.48 160.92 71.58 Favored Pre-proline 0 C--N 1.33 -0.245 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.99 134.57 56.13 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.755 1.637 . . . . 0.0 111.795 -179.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.421 ' O ' ' CB ' ' A' ' 5' ' ' SER . . . -86.15 156.33 20.39 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.454 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.537 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 38.1 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.889 0.376 . . . . 0.0 110.638 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.9 mt 39.6 78.03 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.519 178.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -162.9 176.52 39.17 Favored Glycine 0 CA--C 1.529 0.934 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.216 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.3 m -107.93 -9.98 15.6 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.545 0.212 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.431 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -65.34 146.23 98.98 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.57 -179.502 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.2 -16.0 39.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 122.477 2.118 . . . . 0.0 112.264 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.7 m-85 -88.23 154.44 20.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.181 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -96.49 152.6 18.47 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.172 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.16 -92.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.207 -179.725 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.73 -24.85 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.632 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 mt -90.13 -2.68 58.11 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.763 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.8 -21.13 37.95 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.2 m-85 -70.78 154.29 94.38 Favored Pre-proline 0 C--N 1.329 -0.322 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -44.55 136.88 8.77 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.072 1.848 . . . . 0.0 112.065 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -88.52 156.62 18.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.53 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.541 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.31 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 120.781 0.324 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.603 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.2 mp 35.75 79.74 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.534 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.69 176.38 35.59 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.6 m -105.43 -3.3 22.74 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.625 0.25 . . . . 0.0 111.091 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 1.1 t -74.94 145.36 81.07 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.554 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.34 -15.1 38.45 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.293 1.996 . . . . 0.0 111.801 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.456 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.6 m-85 -88.41 161.07 17.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.35 -179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -100.06 153.21 19.4 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.836 0.35 . . . . 0.0 110.604 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.2 OUTLIER -88.0 -84.46 0.2 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.84 -179.781 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 15.6 pt -143.69 -23.03 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.645 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 84.6 mt -88.12 -5.83 58.23 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.075 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.61 -19.06 55.67 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -71.41 172.01 7.69 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -62.13 143.27 94.43 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 121.654 1.569 . . . . 0.0 111.8 -178.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.456 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -92.25 155.72 17.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.173 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.482 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.466 0.368 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.544 -179.244 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.588 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.8 mp 37.93 79.2 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.617 179.171 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.85 165.31 34.6 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.3 m -91.12 -12.06 36.68 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.628 0.251 . . . . 0.0 111.35 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.447 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -65.36 144.49 99.0 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.7 -179.37 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.76 -15.76 37.25 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.354 2.036 . . . . 0.0 111.785 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.506 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.6 m-85 -88.65 161.43 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.291 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -99.26 156.82 16.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.397 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.06 -91.97 0.11 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.123 -179.639 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.6 mt -132.89 -26.23 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.567 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . 0.563 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.05 -3.84 58.56 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.795 -179.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.4 -10.12 71.41 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 18.0 m-85 -83.16 152.54 65.2 Favored Pre-proline 0 C--N 1.329 -0.292 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -37.45 140.08 0.24 Allowed 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.774 2.316 . . . . 0.0 111.997 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -96.77 155.17 16.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.569 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.433 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.464 0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.608 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.1 p . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.113 0.482 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 36.9 77.34 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.865 178.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.18 36.33 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.185 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.4 m -97.51 -5.0 36.84 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.815 -0.226 . . . . 0.0 111.431 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -73.5 146.55 86.33 Favored Pre-proline 0 CA--C 1.539 0.546 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.747 -179.394 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -70.92 -14.56 32.51 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.479 2.12 . . . . 0.0 112.238 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.492 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.9 m-85 -88.47 155.55 19.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.794 0.33 . . . . 0.0 110.608 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -95.46 154.05 17.4 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.695 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.97 -95.87 0.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.16 -179.483 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.06 -24.14 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.558 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.7 mt -90.67 -4.72 56.56 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.808 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.89 -17.35 58.88 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -70.47 170.83 9.33 Favored Pre-proline 0 C--N 1.33 -0.265 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -62.11 142.71 93.15 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 121.878 1.719 . . . . 0.0 111.835 -178.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.492 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -93.41 153.47 18.48 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.663 -0.698 . . . . 0.0 111.198 -178.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.513 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER . . . . . 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.681 -179.408 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.0 p . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.75 0.309 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 41.38 77.55 0.06 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.214 0.531 . . . . 0.0 111.44 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -166.04 175.51 41.57 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.4 m -113.17 -1.94 14.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.449 0.166 . . . . 0.0 110.726 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.5 t -66.52 134.06 94.38 Favored Pre-proline 0 CA--C 1.538 0.487 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.736 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -47.65 -31.08 13.59 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 121.794 1.663 . . . . 0.0 112.516 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . 0.564 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.1 161.94 17.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.197 -178.845 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.657 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 8.4 p30 -100.59 170.28 8.48 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.19 179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.519 ' N ' ' HB2' ' A' ' 15' ' ' ALA . 0.0 OUTLIER -89.83 -87.23 0.18 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.192 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.414 HG21 HD13 ' A' ' 10' ' ' ILE . 18.0 pt -146.36 -18.64 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.655 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.1 mt -89.0 -1.73 58.25 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.862 0.363 . . . . 0.0 110.03 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.42 -13.76 66.84 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 36.1 m-85 -81.48 154.43 71.43 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -49.55 128.8 21.72 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 121.969 1.779 . . . . 0.0 112.112 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.657 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -83.48 162.49 20.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.618 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.484 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.585 -179.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.529 0.146 0 CA-C-O 120.975 0.417 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.602 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.3 mp 37.24 81.58 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.533 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.55 168.34 35.38 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 111.389 -0.685 . . . . 0.0 111.389 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 15.8 m -93.07 -17.62 23.61 Favored 'General case' 0 N--CA 1.466 0.325 0 O-C-N 122.664 -0.315 . . . . 0.0 110.929 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.57 145.03 78.13 Favored Pre-proline 0 CA--C 1.539 0.521 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.773 -179.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -69.41 -19.54 37.66 Favored 'Trans proline' 0 N--CA 1.496 1.658 0 C-N-CA 122.535 2.157 . . . . 0.0 112.178 -179.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -88.86 166.08 14.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.843 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.552 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 9.8 p30 -101.53 159.67 15.1 Favored 'General case' 0 C--N 1.332 -0.196 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.282 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.479 ' N ' ' HB2' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -91.1 -93.9 0.13 Allowed 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.564 179.597 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.51 -24.85 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.771 -0.65 . . . . 0.0 110.444 -179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.547 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.08 -0.99 57.89 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.359 -179.818 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 87.73 -9.85 72.35 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 5.5 m-85 -82.71 152.8 67.04 Favored Pre-proline 0 C--N 1.329 -0.297 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -41.88 118.25 0.88 Allowed 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 122.458 2.106 . . . . 0.0 111.99 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.552 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -75.09 159.53 31.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.969 179.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.493 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -103.17 46.37 0.92 Allowed 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.206 -179.446 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 89.3 mt -89.69 111.1 22.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.885 179.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -139.63 168.09 18.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.284 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.443 ' O ' HG22 ' A' ' 19' ' ' ILE . 96.3 mt -87.32 -13.91 10.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.556 -179.764 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 8.4 p90 -143.01 149.55 49.63 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.599 -0.273 . . . . 0.0 110.514 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.491 1.372 0 C-N-CA 122.366 2.044 . . . . 0.0 111.963 179.76 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 12.9 p . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.003 0.43 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.648 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.1 mp 38.07 79.14 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.72 178.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.28 -177.27 33.22 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 4.1 m -111.19 -23.89 10.6 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.506 ' HB2' ' H ' ' A' ' 17' ' ' ILE . 1.3 t -52.18 145.31 19.02 Favored Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.709 -179.257 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -68.4 -15.12 41.6 Favored 'Trans proline' 0 N--CA 1.497 1.71 0 C-N-CA 122.338 2.025 . . . . 0.0 111.905 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.465 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.5 m-85 -88.09 156.08 19.46 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.01 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -99.27 153.86 18.62 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.226 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.415 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.6 OUTLIER -88.48 -93.44 0.11 Allowed 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.631 -179.737 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -131.24 -24.88 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.914 -179.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.568 HD22 ' N ' ' A' ' 11' ' ' LEU . 2.9 mm? -89.74 -5.57 56.86 Favored 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 120.541 -0.463 . . . . 0.0 110.533 -179.474 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 96.06 -26.94 18.6 Favored Glycine 0 CA--C 1.522 0.491 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -61.33 168.93 2.58 Favored Pre-proline 0 C--N 1.328 -0.338 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 178.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_exo -62.35 144.04 94.58 Favored 'Trans proline' 0 C--N 1.309 -1.512 0 C-N-CA 121.44 1.426 . . . . 0.0 112.025 -178.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.465 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -89.85 153.76 20.4 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.706 -178.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.547 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER -103.55 59.0 0.74 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.402 -179.353 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.506 ' H ' ' HB2' ' A' ' 5' ' ' SER . 97.4 mt -89.02 -40.13 13.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.469 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -88.71 27.45 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.833 0.349 . . . . 0.0 110.429 179.686 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 21.1 tt -89.16 -15.04 9.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.182 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.63 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 35.2 m-85 50.79 76.54 0.53 Allowed Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.405 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 79.7 Cg_exo . . . . . 0 C--N 1.308 -1.559 0 C-N-CA 122.629 2.219 . . . . 0.0 112.17 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.941 0.4 . . . . 0.0 110.682 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 13.4 mt 38.85 77.9 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.649 178.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.89 169.47 35.19 Favored Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.392 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 64.3 m -98.06 -6.01 32.7 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.619 0.247 . . . . 0.0 111.152 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.442 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -71.59 144.59 88.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.8 -179.355 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.96 -15.84 40.43 Favored 'Trans proline' 0 N--CA 1.495 1.563 0 C-N-CA 122.195 1.93 . . . . 0.0 112.13 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.518 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.8 m-85 -88.21 160.7 17.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.382 -179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -100.21 153.17 19.49 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.432 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.03 -96.85 0.09 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.827 179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 1.6 pt -129.62 -21.38 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.568 179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 32.0 mt -91.13 -2.81 57.5 Favored 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.541 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.21 -18.53 53.87 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -77.83 151.11 79.26 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.764 0.316 . . . . 0.0 110.228 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -36.02 139.85 0.15 Allowed 'Trans proline' 0 C--N 1.307 -1.65 0 C-N-CA 122.835 2.357 . . . . 0.0 111.881 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.518 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -94.72 160.01 14.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.34 -179.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -111.57 51.17 0.8 Allowed 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.594 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 40.8 pt -89.33 12.3 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.547 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 19' ' ' ILE . 1.4 t -77.48 -148.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.105 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.529 ' H ' HG12 ' A' ' 18' ' ' VAL . 96.4 mt -89.83 -39.53 12.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.683 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 78.7 m-85 -43.25 147.96 0.68 Allowed Pre-proline 0 CA--C 1.534 0.357 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.661 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 81.3 Cg_exo . . . . . 0 N--CA 1.49 1.296 0 C-N-CA 122.29 1.993 . . . . 0.0 111.995 179.639 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 99.3 p . . . . . 0 CA--C 1.523 -0.081 0 CA-C-O 120.847 0.356 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.606 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.4 mp 38.19 79.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.033 179.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -165.67 178.69 40.37 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 -179.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.2 p -107.43 -31.75 8.02 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-O 120.789 0.328 . . . . 0.0 111.345 -179.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.3 t -39.84 130.55 1.51 Allowed Pre-proline 0 CA--C 1.547 0.836 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.21 -179.242 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_exo -49.21 -26.94 11.91 Favored 'Trans proline' 0 N--CA 1.497 1.716 0 C-N-CA 121.818 1.678 . . . . 0.0 112.28 179.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.595 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.23 161.87 16.97 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.076 -178.778 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.647 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 4.8 p-10 -100.68 170.9 8.04 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.455 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.523 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -91.22 -97.95 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.105 179.705 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.7 mt -131.53 -22.45 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.478 -179.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 33.7 mt -87.24 -4.21 59.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.901 0.382 . . . . 0.0 110.409 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.66 -15.56 63.07 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 16.8 m-85 -75.77 158.21 83.04 Favored Pre-proline 0 C--N 1.328 -0.368 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo -52.99 132.49 47.72 Favored 'Trans proline' 0 C--N 1.305 -1.748 0 C-N-CA 121.558 1.506 . . . . 0.0 111.74 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.647 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -87.52 160.18 18.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.692 -179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.513 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -103.02 41.71 1.23 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.642 -179.035 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.8 mt -89.85 124.92 42.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.463 179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -124.7 -94.44 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.415 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.9 mt -136.16 -36.41 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.585 ' N ' ' CD ' ' A' ' 21' ' ' PRO . 0.0 OUTLIER -78.5 -43.55 2.01 Favored Pre-proline 0 CA--C 1.533 0.326 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.298 -179.835 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.585 ' CD ' ' N ' ' A' ' 20' ' ' TYR . 52.1 Cg_exo . . . . . 0 N--CA 1.496 1.622 0 C-N-CA 122.495 2.13 . . . . 0.0 112.16 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 26.4 p . . . . . 0 N--CA 1.455 -0.207 0 CA-C-O 120.714 0.292 . . . . 0.0 110.456 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.5 mt 41.12 60.97 1.88 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.143 0.497 . . . . 0.0 111.026 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -147.51 -169.48 14.87 Favored Glycine 0 CA--C 1.521 0.459 0 N-CA-C 110.826 -0.91 . . . . 0.0 110.826 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 10.2 m -136.77 0.63 2.46 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 120.789 0.328 . . . . 0.0 110.485 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.426 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 5.5 t -66.43 142.84 97.94 Favored Pre-proline 0 CA--C 1.537 0.476 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.714 -179.399 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -45.91 -38.53 18.37 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.887 1.725 . . . . 0.0 112.294 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.489 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 4.3 m-85 -88.61 163.96 15.59 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.318 -179.273 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.613 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 82.2 m-20 -101.56 171.19 7.71 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.186 179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -89.65 -94.54 0.11 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.393 179.83 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.7 -23.71 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 29.1 mt -86.36 -2.03 58.06 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.3 -179.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 92.37 -12.78 68.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.814 -0.914 . . . . 0.0 110.814 179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -82.08 150.66 65.33 Favored Pre-proline 0 C--N 1.33 -0.279 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -40.61 133.94 2.32 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 C-N-CA 122.597 2.198 . . . . 0.0 112.049 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.613 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -88.15 161.16 17.43 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.027 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -115.24 62.12 0.69 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.383 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.5 pt -89.28 17.88 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.524 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 28.2 m -74.98 159.34 5.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.388 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.452 HG23 ' N ' ' A' ' 20' ' ' TYR . 20.9 tt -88.06 -38.45 11.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.591 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.452 ' N ' HG23 ' A' ' 19' ' ' ILE . 2.6 p90 -86.48 151.35 53.18 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.485 -179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo . . . . . 0 C--N 1.313 -1.319 0 C-N-CA 122.495 2.13 . . . . 0.0 111.994 179.745 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.864 0.364 . . . . 0.0 110.826 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.409 ' O ' HD22 ' A' ' 16' ' ' LEU . 10.9 mt 41.86 66.32 0.73 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.746 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -148.48 -171.35 17.25 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 69.6 m -130.2 -3.94 4.42 Favored 'General case' 0 C--N 1.331 -0.207 0 O-C-N 122.752 -0.263 . . . . 0.0 110.512 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.406 ' OG ' ' CG1' ' A' ' 17' ' ' ILE . 6.1 t -66.46 140.19 96.49 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.734 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -45.74 -37.24 15.84 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.64 2.227 . . . . 0.0 112.25 179.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.492 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 4.1 m-85 -89.42 164.35 14.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.495 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.626 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 71.7 m-80 -101.36 173.13 6.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.982 0.42 . . . . 0.0 110.449 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.42 -81.9 0.25 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.334 179.749 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 17.6 pt -148.46 -36.6 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.49 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 75.5 mt -66.76 -40.95 88.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.654 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 141.48 -27.6 2.36 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -72.44 156.83 89.96 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.905 0.383 . . . . 0.0 110.621 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -49.38 138.49 30.27 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.332 2.021 . . . . 0.0 112.192 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.626 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -85.27 164.0 18.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.379 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.409 HD22 ' O ' ' A' ' 2' ' ' LEU . 0.4 OUTLIER -118.64 67.16 0.77 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.282 179.827 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.406 ' CG1' ' OG ' ' A' ' 5' ' ' SER . 5.7 pt -88.9 115.47 28.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-O 121.299 0.571 . . . . 0.0 110.385 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.641 HG22 ' H ' ' A' ' 20' ' ' TYR . 3.2 p -142.66 141.73 27.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.412 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.0 mt -89.72 -17.67 8.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.769 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.641 ' H ' HG22 ' A' ' 18' ' ' VAL . 13.5 p90 -124.92 80.0 63.96 Favored Pre-proline 0 C--N 1.331 -0.198 0 CA-C-O 121.085 0.469 . . . . 0.0 110.476 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_exo . . . . . 0 C--N 1.307 -1.643 0 C-N-CA 122.741 2.294 . . . . 0.0 112.073 -179.918 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 15.2 p . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.827 0.346 . . . . 0.0 110.359 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.5 mt 39.67 79.27 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.216 179.357 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -163.66 178.19 39.25 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.9 m -106.0 -25.86 11.91 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.893 0.378 . . . . 0.0 110.562 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.416 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.3 OUTLIER -48.08 145.4 5.07 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.661 -179.355 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -68.79 -18.99 41.58 Favored 'Trans proline' 0 N--CA 1.495 1.579 0 C-N-CA 122.528 2.152 . . . . 0.0 112.18 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.468 ' O ' ' N ' ' A' ' 15' ' ' ALA . 91.2 m-85 -88.61 156.93 18.76 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.479 ' OD1' ' N ' ' A' ' 8' ' ' ASN . 3.1 p-10 -96.27 155.77 16.62 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.915 0.388 . . . . 0.0 110.283 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.55 -92.01 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.392 -179.588 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.8 mt -132.56 -25.68 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.529 -179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 66.8 mt -88.84 -1.55 58.15 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.538 -179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 88.69 -11.4 68.69 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 41.4 m-85 -82.04 150.69 65.54 Favored Pre-proline 0 C--N 1.331 -0.224 0 CA-C-O 120.833 0.349 . . . . 0.0 110.356 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -36.76 132.53 0.4 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.736 2.291 . . . . 0.0 111.893 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.468 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -87.4 157.14 19.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.972 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.511 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.4 OUTLIER -100.74 39.41 1.38 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.276 -179.601 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -89.24 124.44 41.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.252 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.7 t -140.12 -90.59 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.774 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 19.8 tt -96.95 -13.89 7.95 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-O 120.762 0.315 . . . . 0.0 110.336 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.447 ' CD1' ' C ' ' A' ' 20' ' ' TYR . 19.4 p90 -141.69 146.31 40.83 Favored Pre-proline 0 CA--C 1.536 0.424 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.636 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo . . . . . 0 N--CA 1.496 1.621 0 C-N-CA 122.448 2.099 . . . . 0.0 111.855 179.191 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 75.6 p . . . . . 0 N--CA 1.457 -0.12 0 CA-C-O 120.994 0.426 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.4 mt 41.58 67.98 0.5 Allowed 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.521 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -154.3 -166.28 14.82 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 14.2 m -134.72 -0.33 2.87 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.675 0.274 . . . . 0.0 110.768 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.48 ' N ' ' O ' ' A' ' 15' ' ' ALA . 5.7 t -64.21 141.79 98.17 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.686 -179.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_exo -46.56 -39.4 22.77 Favored 'Trans proline' 0 N--CA 1.495 1.611 0 C-N-CA 121.914 1.743 . . . . 0.0 112.739 179.231 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.479 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 6.7 m-85 -89.05 167.95 12.74 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.384 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.541 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 8.8 m120 -100.76 171.04 7.93 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.535 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.0 OUTLIER -88.13 -92.4 0.11 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.061 -179.698 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 97.0 mt -134.67 -39.47 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.874 -179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 48.9 mt -67.49 -39.91 85.23 Favored 'General case' 0 C--N 1.329 -0.306 0 C-N-CA 120.308 -0.557 . . . . 0.0 110.648 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 137.44 -24.2 3.08 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -68.76 158.96 84.32 Favored Pre-proline 0 C--N 1.33 -0.244 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.419 ' HA ' HD22 ' A' ' 8' ' ' ASN . 51.1 Cg_exo -51.31 130.72 33.58 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.017 1.811 . . . . 0.0 112.125 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.541 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -74.95 152.25 38.8 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.53 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.3 OUTLIER -96.57 35.86 1.45 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.953 0.406 . . . . 0.0 110.382 -179.726 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.6 mt -92.68 113.49 27.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.269 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.0 t -146.83 -80.99 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.12 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -93.03 -50.11 12.45 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.572 -0.285 . . . . 0.0 110.825 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.405 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 2.7 p90 -102.25 151.23 38.08 Favored Pre-proline 0 N--CA 1.467 0.414 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.573 -179.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo . . . . . 0 N--CA 1.493 1.472 0 C-N-CA 122.541 2.16 . . . . 0.0 111.762 179.54 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 83.3 p . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.788 0.328 . . . . 0.0 110.568 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.591 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.4 mp 37.47 78.73 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.282 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.11 170.82 34.97 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 3.7 t -88.59 -40.74 13.14 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.082 0.468 . . . . 0.0 110.771 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.413 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.6 OUTLIER -40.51 143.65 0.65 Allowed Pre-proline 0 CA--C 1.539 0.552 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.183 -179.1 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -71.85 -12.99 29.14 Favored 'Trans proline' 0 N--CA 1.498 1.74 0 C-N-CA 122.353 2.035 . . . . 0.0 111.846 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.8 m-85 -88.38 161.82 16.87 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.413 -179.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.419 ' ND2' ' O ' ' A' ' 12' ' ' GLY . 98.9 m-20 -98.26 156.16 16.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.237 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.524 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.82 -99.03 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.827 -0.624 . . . . 0.0 109.411 179.75 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.3 pt -128.63 -19.77 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.598 -0.274 . . . . 0.0 110.504 179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 13.3 mt -91.87 -5.42 53.35 Favored 'General case' 0 N--CA 1.465 0.312 0 C-N-CA 120.544 -0.463 . . . . 0.0 110.303 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.419 ' O ' ' ND2' ' A' ' 8' ' ' ASN . . . 94.86 -8.88 70.78 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.526 -1.03 . . . . 0.0 110.526 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.427 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 8.9 m-85 -86.05 153.7 57.31 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-O 120.825 0.345 . . . . 0.0 110.154 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_exo -37.23 141.49 0.18 Allowed 'Trans proline' 0 C--N 1.306 -1.683 0 C-N-CA 123.0 2.466 . . . . 0.0 112.0 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.521 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -99.45 155.32 17.62 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.703 -179.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.424 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER -110.5 51.93 0.75 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.483 -179.621 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 39.0 pt -90.32 5.51 5.27 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 CA-C-O 120.883 0.373 . . . . 0.0 110.545 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.8 m -72.99 171.83 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.439 179.738 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 16.4 tt -87.76 -27.57 5.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.735 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -73.32 146.84 87.12 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.425 -179.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 76.8 Cg_exo . . . . . 0 N--CA 1.492 1.404 0 C-N-CA 122.152 1.901 . . . . 0.0 112.315 179.677 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 84.0 p . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.909 0.385 . . . . 0.0 110.499 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.587 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.3 mp 38.04 72.14 0.13 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.135 179.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.61 -167.42 19.37 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.675 -0.97 . . . . 0.0 110.675 179.778 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 17.6 m -135.58 1.3 2.83 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.704 0.288 . . . . 0.0 110.847 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.421 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 7.0 t -66.96 144.6 98.62 Favored Pre-proline 0 CA--C 1.538 0.517 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.028 -179.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -51.06 -34.94 49.15 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 121.806 1.671 . . . . 0.0 112.075 178.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.46 ' CD1' ' N ' ' A' ' 7' ' ' TYR . 15.7 m-85 -88.04 160.29 17.91 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.065 -178.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -100.25 164.64 11.86 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.285 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.69 -96.88 0.09 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.459 -179.385 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.59 -24.41 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.78 0.324 . . . . 0.0 110.486 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 24.3 mt -88.53 -5.43 58.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-O 120.906 0.384 . . . . 0.0 110.285 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.44 -9.19 74.49 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.859 -0.897 . . . . 0.0 110.859 179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -78.48 160.92 71.58 Favored Pre-proline 0 C--N 1.33 -0.245 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_exo -52.99 134.57 56.13 Favored 'Trans proline' 0 C--N 1.306 -1.681 0 C-N-CA 121.755 1.637 . . . . 0.0 111.795 -179.262 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.421 ' O ' ' CB ' ' A' ' 5' ' ' SER . . . -86.15 156.33 20.39 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.454 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.6 OUTLIER -109.63 50.2 0.8 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.537 -179.833 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 35.8 pt -89.36 45.96 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-O 120.849 0.357 . . . . 0.0 110.705 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.431 ' H ' HG22 ' A' ' 18' ' ' VAL . 15.6 m -88.9 172.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.418 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.441 HG23 ' N ' ' A' ' 20' ' ' TYR . 20.4 tt -88.61 -38.13 11.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.689 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.441 ' N ' HG23 ' A' ' 19' ' ' ILE . 3.2 p90 -82.31 152.56 67.79 Favored Pre-proline 0 CA--C 1.535 0.376 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.103 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo . . . . . 0 N--CA 1.49 1.294 0 C-N-CA 122.404 2.069 . . . . 0.0 112.393 179.681 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 38.1 p . . . . . 0 CA--C 1.527 0.072 0 CA-C-O 120.889 0.376 . . . . 0.0 110.638 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 11.9 mt 39.6 78.03 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.519 178.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -162.9 176.52 39.17 Favored Glycine 0 CA--C 1.529 0.934 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.216 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 65.3 m -107.93 -9.98 15.6 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.545 0.212 . . . . 0.0 111.11 -179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.431 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -65.34 146.23 98.98 Favored Pre-proline 0 CA--C 1.539 0.537 0 CA-C-N 116.62 -0.264 . . . . 0.0 110.57 -179.502 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -69.2 -16.0 39.58 Favored 'Trans proline' 0 N--CA 1.498 1.758 0 C-N-CA 122.477 2.118 . . . . 0.0 112.264 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 15' ' ' ALA . 93.7 m-85 -88.23 154.44 20.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.181 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.1 m-20 -96.49 152.6 18.47 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.172 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -88.16 -92.64 0.11 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.207 -179.725 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.2 mt -132.73 -24.85 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.632 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 25.5 mt -90.13 -2.68 58.11 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.763 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.8 -21.13 37.95 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.2 m-85 -70.78 154.29 94.38 Favored Pre-proline 0 C--N 1.329 -0.322 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 179.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -44.55 136.88 8.77 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.072 1.848 . . . . 0.0 112.065 179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.437 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -88.52 156.62 18.98 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.53 -179.53 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.541 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -100.58 43.59 1.05 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.31 -179.9 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.5 mt -89.82 117.41 33.07 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.226 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 32.8 m -137.03 167.47 23.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.226 -179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 26.9 mm -86.62 -38.86 12.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.865 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.571 ' O ' ' CD2' ' A' ' 20' ' ' TYR . 14.8 p90 -116.15 82.65 11.63 Favored Pre-proline 0 N--CA 1.468 0.428 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.584 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_exo . . . . . 0 C--N 1.307 -1.621 0 C-N-CA 122.296 1.998 . . . . 0.0 112.147 179.938 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.457 -0.125 0 CA-C-O 120.781 0.324 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.603 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.2 mp 35.75 79.74 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.534 179.327 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -158.69 176.38 35.59 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 70.6 m -105.43 -3.3 22.74 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.625 0.25 . . . . 0.0 111.091 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.446 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 1.1 t -74.94 145.36 81.07 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 120.931 -0.307 . . . . 0.0 110.554 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -69.34 -15.1 38.45 Favored 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.293 1.996 . . . . 0.0 111.801 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.456 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.6 m-85 -88.41 161.07 17.28 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.35 -179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.8 m120 -100.06 153.21 19.4 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.836 0.35 . . . . 0.0 110.604 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.2 OUTLIER -88.0 -84.46 0.2 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.84 -179.781 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 15.6 pt -143.69 -23.03 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.645 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 84.6 mt -88.12 -5.83 58.23 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.075 179.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.61 -19.06 55.67 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.4 m-85 -71.41 172.01 7.69 Favored Pre-proline 0 C--N 1.329 -0.323 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -62.13 143.27 94.43 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 121.654 1.569 . . . . 0.0 111.8 -178.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.456 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -92.25 155.72 17.78 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.173 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.482 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -107.76 47.15 0.91 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.544 -179.244 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 43.5 pt -90.24 10.44 2.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.745 -179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 t -69.8 -126.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.377 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.466 HG23 ' N ' ' A' ' 20' ' ' TYR . 10.4 tp -89.64 -39.79 12.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.166 0 CA-C-O 120.751 0.31 . . . . 0.0 110.651 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.466 ' N ' HG23 ' A' ' 19' ' ' ILE . 63.3 m-85 -43.21 150.91 0.45 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.52 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo . . . . . 0 N--CA 1.491 1.327 0 C-N-CA 122.336 2.024 . . . . 0.0 112.3 179.755 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.967 0.413 . . . . 0.0 111.007 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.588 HD12 ' H ' ' A' ' 2' ' ' LEU . 10.8 mp 37.93 79.2 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.617 179.171 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -159.85 165.31 34.6 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.3 m -91.12 -12.06 36.68 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.628 0.251 . . . . 0.0 111.35 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.447 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.9 OUTLIER -65.36 144.49 99.0 Favored Pre-proline 0 CA--C 1.539 0.524 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.7 -179.37 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -69.76 -15.76 37.25 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.354 2.036 . . . . 0.0 111.785 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.506 ' O ' ' N ' ' A' ' 15' ' ' ALA . 94.6 m-85 -88.65 161.43 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.291 -179.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -99.26 156.82 16.78 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.397 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -88.06 -91.97 0.11 Allowed 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.123 -179.639 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 96.6 mt -132.89 -26.23 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.567 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . 0.563 HD22 ' N ' ' A' ' 11' ' ' LEU . 3.6 mm? -89.05 -3.84 58.56 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.795 -179.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 94.4 -10.12 71.41 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.4 ' O ' ' OD1' ' A' ' 9' ' ' ASP . 18.0 m-85 -83.16 152.54 65.2 Favored Pre-proline 0 C--N 1.329 -0.292 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_exo -37.45 140.08 0.24 Allowed 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.774 2.316 . . . . 0.0 111.997 179.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -96.77 155.17 16.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.569 -179.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.433 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -109.89 53.35 0.69 Allowed 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.608 -179.3 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 40.2 pt -91.8 -3.02 10.62 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.125 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.683 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.2 m -54.59 172.42 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.475 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 96.4 mt -89.69 -41.12 13.55 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.637 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -82.2 152.4 67.9 Favored Pre-proline 0 CA--C 1.535 0.402 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.383 -179.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_exo . . . . . 0 N--CA 1.49 1.318 0 C-N-CA 122.413 2.076 . . . . 0.0 112.286 179.813 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 85.1 p . . . . . 0 C--O 1.232 0.153 0 CA-C-O 121.113 0.482 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 36.9 77.34 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.589 -0.732 . . . . 0.0 111.865 178.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -160.68 169.18 36.33 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 115.512 -0.767 . . . . 0.0 111.185 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 66.4 m -97.51 -5.0 36.84 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.815 -0.226 . . . . 0.0 111.431 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.45 ' CB ' ' O ' ' A' ' 15' ' ' ALA . 0.4 OUTLIER -73.5 146.55 86.33 Favored Pre-proline 0 CA--C 1.539 0.546 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.747 -179.394 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -70.92 -14.56 32.51 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.479 2.12 . . . . 0.0 112.238 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.492 ' O ' ' N ' ' A' ' 15' ' ' ALA . 96.9 m-85 -88.47 155.55 19.6 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.794 0.33 . . . . 0.0 110.608 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 -95.46 154.05 17.4 Favored 'General case' 0 CA--C 1.519 -0.226 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.695 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.466 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.1 OUTLIER -87.97 -95.87 0.09 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.16 -179.483 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 95.3 mt -131.06 -24.14 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.789 0.328 . . . . 0.0 110.558 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 39.7 mt -90.67 -4.72 56.56 Favored 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.808 -179.603 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.89 -17.35 58.88 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 1.6 m-85 -70.47 170.83 9.33 Favored Pre-proline 0 C--N 1.33 -0.265 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 179.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -62.11 142.71 93.15 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 C-N-CA 121.878 1.719 . . . . 0.0 111.835 -178.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.492 ' N ' ' O ' ' A' ' 7' ' ' TYR . . . -93.41 153.47 18.48 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.663 -0.698 . . . . 0.0 111.198 -178.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.513 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.5 OUTLIER -103.24 26.36 8.41 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.681 -179.408 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 pt -89.06 136.97 22.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.122 0.487 . . . . 0.0 110.734 -179.468 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.0 m -143.78 -170.01 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.272 -179.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 30.4 mm -87.8 -21.8 7.0 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.413 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.453 ' CD1' ' N ' ' A' ' 20' ' ' TYR . 0.1 OUTLIER -135.4 63.79 56.5 Favored Pre-proline 0 N--CA 1.468 0.435 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.287 -179.773 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 93.9 Cg_endo . . . . . 0 C--N 1.306 -1.69 0 C-N-CA 122.632 2.221 . . . . 0.0 111.998 -179.724 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' SER . . . . . . . . . . . . . 60.0 p . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.75 0.309 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 12.0 mt 41.38 77.55 0.06 Allowed 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.214 0.531 . . . . 0.0 111.44 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -166.04 175.51 41.57 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 68.4 m -113.17 -1.94 14.24 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.449 0.166 . . . . 0.0 110.726 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.5 t -66.52 134.06 94.38 Favored Pre-proline 0 CA--C 1.538 0.487 0 C-N-CA 120.636 -0.426 . . . . 0.0 110.736 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo -47.65 -31.08 13.59 Favored 'Trans proline' 0 N--CA 1.494 1.55 0 C-N-CA 121.794 1.663 . . . . 0.0 112.516 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.564 ' N ' ' CD1' ' A' ' 7' ' ' TYR . 0.2 OUTLIER -88.1 161.94 17.03 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.197 -178.845 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.657 ' C ' ' HB2' ' A' ' 15' ' ' ALA . 8.4 p30 -100.59 170.28 8.48 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.19 179.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.519 ' N ' ' HB2' ' A' ' 15' ' ' ALA . 0.0 OUTLIER -89.83 -87.23 0.18 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.192 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.414 HG21 HD13 ' A' ' 10' ' ' ILE . 18.0 pt -146.36 -18.64 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.655 -179.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LEU . . . . . . . . . . . . . 71.1 mt -89.0 -1.73 58.25 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.862 0.363 . . . . 0.0 110.03 179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 93.42 -13.76 66.84 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.889 -0.884 . . . . 0.0 110.889 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 36.1 m-85 -81.48 154.43 71.43 Favored Pre-proline 0 C--N 1.329 -0.312 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -49.55 128.8 21.72 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 C-N-CA 121.969 1.779 . . . . 0.0 112.112 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.657 ' HB2' ' C ' ' A' ' 8' ' ' ASN . . . -83.48 162.49 20.92 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.618 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.484 ' H ' HD23 ' A' ' 16' ' ' LEU . 0.4 OUTLIER -103.16 40.58 1.37 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.585 -179.205 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 96.9 mt -89.61 92.32 3.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.405 179.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.39 -74.76 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.16 179.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.578 HG23 ' N ' ' A' ' 20' ' ' TYR . 10.3 tp -133.2 -46.01 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.643 179.771 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.578 ' N ' HG23 ' A' ' 19' ' ' ILE . 32.4 p90 -91.0 146.42 33.66 Favored Pre-proline 0 N--CA 1.466 0.338 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.773 -179.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.7 Cg_endo . . . . . 0 N--CA 1.495 1.561 0 C-N-CA 122.162 1.908 . . . . 0.0 111.71 179.868 . . . . . . . . 0 0 . 1 stop_ save_